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It is essential that themedical profession play a central role in
critically evaluating the evidence related to drugs, devices,
and procedures for the detection,management, or prevention
of disease. Properly applied, rigorous, expert analysis of the
available data documenting absolute and relative benefits andgery c December 2011
Gersh et al Clinical Guidelinerisks of these therapies andprocedures can improve the effec-
tiveness of care, optimize patient outcomes, and favorably
fnect the cost of care by focusing resources on themost effec-
tive strategies. One important use of such data is the produc-
tion of clinical practice guidelines that, in turn, can provide
a foundation for a variety of other applications such as perfor-
mance measures, appropriateness use criteria, clinical deci-
sion support tools, and quality improvement tools.
The American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
jointly engaged in the production of guidelines in the area
of cardiovascular disease since 1980. The ACCF/AHA
Task Force on Practice Guidelines (Task Force) is charged
with developing, updating, and revising practice guidelines
for cardiovascular diseases and procedures, and the Task
Force directs and oversees this effort. Writing committees
are charged with assessing the evidence as an independent
group of authors to develop, update, or revise recommenda-
tions for clinical practice.
Experts in the subject under consideration have been se-
lected from both organizations to examine subject-specific
data and write guidelines in partnership with representatives
from other medical practitioner and specialty groups. Writ-
ing committees are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against particular tests, treatments, or procedures, and in-
clude estimates of expected health outcomes where data ex-
ist. Patient-specific modifiers, comorbidities, and issues of
patient preference that may influence the choice of tests
or therapies are considered. When available, information
from studies on cost is considered, but data on efficacy
and clinical outcomes constitute the primary basis for rec-
ommendations in these guidelines.
In analyzing the data and developing the recommenda-
tions and supporting text, the writing committee used
evidence-based methodologies developed by the Task
Force, which are described elsewhere.1 The committee re-
viewed and ranked evidence supporting current recommen-
dations with the weight of evidence ranked as Level A if the
data were derived from multiple randomized clinical trials
(RCTs) or meta-analyses. The committee ranked available
evidence as Level B when data were derived from a single
RCT or nonrandomized studies. Evidence was ranked as
Level C when the primary source of the recommendation
was consensus opinion, case studies, or standard of care.
In the narrative portions of these guidelines, evidence is
generally presented in chronological order of development.
Studies are identified as observational, retrospective, pro-
spective, or randomized when appropriate. For certain
conditions for which inadequate data are available, recom-
mendations are based on expert consensus and clinical ex-
perience and ranked as Level C. An example is the use of
penicillin for pneumococcal pneumonia, for which there
are no RCTs and treatment is based on clinical experience.The Journal of Thoracic and CarWhen recommendations at Level C are supported by histor-
ical clinical data, appropriate references (including clinical
reviews) are cited if available. For issues where sparse data
are available, a survey of current practice among the clini-
cians on the writing committee was the basis for Level C
recommendations and no references are cited. The schema
for Classification of Recommendations and Level of Evi-
dence is summarized in Table 1, which also illustrates
how the grading system provides an estimate of the size
and the certainty of the treatment effect. A new addition
to the ACCF/AHA methodology is separation of the Class
III recommendations to delineate whether the recommenda-
tion is determined to be of ‘‘no benefit’’ or associated with
‘‘harm’’ to the patient. In addition, in view of the increasing
number of comparative effectiveness studies, comparator
verbs and suggested phrases for writing recommendations
for the comparative effectiveness of one treatment/strategy
with respect to another for Class of Recommendation I and
IIa, Level of Evidence A or B only have been added.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a re-
sult of relationships with industry and other entities (RWI)
among the writing committee. Specifically, all members of
the writing committee, as well as peer reviewers of the doc-
ument, are required to disclose all relevant relationships and
those 12 months prior to initiation of the writing effort. The
policies and procedures for RWI for this guideline were
those in effect at the initial meeting of this committee
(March 28, 2009), which included 50% of the writing com-
mittee with no relevant RWI. All guideline recommenda-
tions require a confidential vote by the writing committee
and must be approved by a consensus of the members vot-
ing. Memberswhowere recused fromvoting are indicated on
the title page of this document with detailed information in-
cluded in Appendix 1. Members must recuse themselves
fromvoting on any recommendationswhere theirRWIapply.
If a writing committee member develops a new RWI during
his/her tenure, he/she is required to notify guideline stfn in
writing. These statements are reviewed by the Task Force
and all members during each conference call and/or meeting
of the writing committee and are updated as changes occur.
For detailed information regarding guideline policies and
procedures, please refer to the ACCF/AHA methodology
and policies manual.1 RWI pertinent to this guideline for au-
thors and peer reviewers are disclosed inAppendixes 1 and 2,
respectively. Comprehensive disclosure information for
the Task Force is also available online at http://www.
cardiosource.org/ACC/About-ACC/Leadership/Guidelines-
and-Documents-Task-Forces.aspx. The work of the writing
committee was supported exclusively by the ACCF and
AHA without commercial support. Writing committee
members volunteered their time for this effort.
The ACCF/AHA practice guidelines address patient popu-
lations (and healthcare providers) residing in North America.diovascular Surgery c Volume 142, Number 6 e155
TABLE 1. Applying classification of recommendation and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction,
history of heart failure, and prior aspirin use. yFor comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of
comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Clinical Guideline Gersh et alAs such, drugs that are currently unavailable inNorthAmerica
are discussed in the text without a specific class of recommen-
dation.For studies performed in largenumbers of subjects out-
side of North America, each writing group reviews the
potential impact of different practice patterns and patient pop-
ulations on the treatment effect and on the relevance to the
ACCF/AHA target population to determine whether the find-
ings should inform a specific recommendation.
The ACCF/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for thee156 The Journal of Thoracic and Cardiovascular Surdiagnosis, management, and prevention of specific diseases
or conditions. These practice guidelines represent a consen-
sus of expert opinion after a thorough review of the available
current scientific evidence and are intended to improve pa-
tient care. The guidelines attempt to define practices that
meet the needs of most patients in most circumstances. The
ultimate judgment regarding care of a particular patient
must be made by the healthcare provider and patient in light
of all the circumstances presented by that patient. Thus, there
are situations in which deviations from these guidelines may
be appropriate. Clinical decision making should consider thegery c December 2011
Gersh et al Clinical Guidelinequality and availability of expertise in the area where care is
provided.When these guidelines are used as the basis for reg-
ulatory or payer decisions, the goal should be improvement
in quality of care. The Task Force recognizes that situations
arise for which additional data are needed to better informpa-
tient care; these areas will be identified within each respec-
tive guideline when appropriate.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed. Be-
cause lack of patient understanding and adherence may ad-
versely fnect outcomes, physicians and other healthcare
providers should make every effort to engage the patient’s ac-
tive participation inprescribedmedical regimens and lifestyles.
The guideline will be reviewed annually by the Task
Force and considered current unless it is updated, revised,
or withdrawn from distribution.
Guidelines are official policy of both the ACCF and
AHA.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
1. INTRODUCTION
1.1. Methodology and Evidence Review
The recommendations listed in this document are, when-
ever possible, evidence based. An extensive evidence re-
view was conducted through January 2011. Searches were
limited to studies, reviews, and other evidence conducted
in human subjects and published in English. Key search
words included, but were not limited to, hypertrophic car-
diomyopathy (HCM), surgical myectomy, ablation, exer-
cise, sudden cardiac death (SCD), athletes, dual-chamber
pacing, left ventricular outflow tract (LVOT) obstruction,
alcohol septal ablation, automobile driving and implant-
able cardioverter-defibrillators (ICDs), catheter ablation,
defibrillators, genetics, genotype, medical management,
magnetic resonance imaging, pacing, permanent pacing,
phenotype, pregnancy, risk stratification, sudden death in
athletes, surgical septal myectomy, and septal reduction.
Additionally, the committee reviewed documents related
to the subject matter previously published by the ACCF
and AHA. References selected and published in this docu-
ment are representative and not all-inclusive.
To provide clinicians with a comprehensive set of data,
whenever deemed appropriate or when published, the abso-
lute risk difference and number needed to treat or harm are
provided in the guideline, along with confidence intervals
and data related to the relative treatment effects, such as
odds ratio, relative risk, hazard ratio, or incidence rate ratio.
1.2. Organization of the Writing Committee
The committee was composed of physicians and cardiac
surgeons with expertise in HCM, invasive cardiology, nonin-
vasive testing and imaging, pediatric cardiology,The Journal of Thoracic and Carelectrophysiology, and genetics. The committee included
representatives from the American Association for Thoracic
Surgery, American Society of Echocardiography, American
Society of Nuclear Cardiology, Heart Failure Society of
America, Heart Rhythm Society, Society for Cardiovascular
Angiography and Interventions, and the Society of Thoracic
Surgeons.1.3. Document Review and Approval
This document was reviewed by 2 outside reviewers
nominated by both the ACCF and AHA, as well as 2 re-
viewers each from the American Association for Thoracic
Surgery, American Society of Echocardiography, American
Society of Nuclear Cardiology, Heart Failure Society of
America, Heart Rhythm Society, Society for Cardiovascu-
lar Angiography and Interventions, and the Society of Tho-
racic Surgeons. Other content reviewers included members
from the ACCFAdult Congenital and Pediatric Cardiology
Council, ACCF Surgeons’ Scientific Council, and ACCF
Interventional Scientific Council. All information on re-
viewers’ RWI was distributed to the writing committee
and is published in this document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACCF and the AHA and endorsed by
the American Association for Thoracic Surgery, American
Society of Echocardiography, American Society of Nuclear
Cardiology, Heart Failure Society of America, Heart
Rhythm Society, Society for Cardiovascular Angiography
and Interventions, and Society of Thoracic Surgeons.1.4. Scope of the Guideline
Although there are reports of this disease dating back to
the 1800s, the first modern pathologic description was pro-
vided over 50 years ago by Teare2 and the most important
early clinical report by Braunwald et al in 1964.3 Since
then, there has been a growing understanding of the com-
plexity and diversity of the underlying genetic substrate,
the clinical phenotype, natural history, and approaches to
treatment.
The impetus for the guideline is based on an appreciation
of the frequency of this clinical entity and a realization that
many aspects of clinical management, including the use of
diagnostic modalities and genetic testing, lack consensus.
Moreover, the emergence of 2 different approaches to septal
reduction therapy (septal myectomy and alcohol septal ab-
lation) in addition to the ICD has created considerable con-
troversy. The discussion and recommendations about the
various diagnostic modalities apply to patients with estab-
lished HCM and to a variable extent to patients with
a high index of suspicion of the disease.
Although the Task Force was aware of the lack of high
levels of evidence regarding HCM provided by clinical tri-
als, it was believed that a guideline document based ondiovascular Surgery c Volume 142, Number 6 e157
Clinical Guideline Gersh et alexpert consensus that outlines the most important diagnos-
tic and management strategies would be helpful.
To facilitate ease of use, it was decided that recommenda-
tions in the pediatric and adolescent age groups would not
appear as a separate section but instead would be integrated
into the overall content of the guideline where relevant.2. PREVALENCE/NOMENCLATURE/
DIFFERENTIAL DIAGNOSIS
2.1. Prevalence
HCM is a common genetic cardiovascular disease. In ad-
dition, HCM is a global disease,4 with epidemiological
studies from several parts of the world5 reporting a similar
prevalence of left ventricular (LV) hypertrophy, the quintes-
sential phenotype of HCM, to be about 0.2% (ie, 1:500) in
the general population, which is equivalent to at least
600,000 people fnected in the United States.6 This esti-
mated frequency in the general population appears to ex-
ceed the relatively uncommon occurrence of HCM in
cardiology practices, implying that most fnected individ-
uals remain unidentified, probably in most cases without
symptoms or shortened life expectancy.2.2. Nomenclature
2.2.1. Historical Context
Although HCM is the preferred nomenclature to describe
this disease,7 confusion over the names used to characterize
the entity of HCM has arisen over the years. At last count,
>80 individual names, terms, and acronyms have been
used (most by early investigators) to describe HCM.7 Fur-
thermore, nomenclature that was popular in the 1960s and
1970s, such as IHSS (idiopathic hypertrophic subaortic ste-
nosis) or HOCM (hypertrophic obstructive cardiomyopa-
thy), is potentially confusing by virtue of the inference that
LVOT is an invariable and obligatory component of the dis-
ease. In fact, fully one third of patients have no obstruction
either at rest or with physiologic provocation.8 Although
terms such as IHSS andHOCMpersist occasionally in infor-
mal usage, they now rarely appear in the literature, whereas
HCM, initially used in 1979, allows for both the obstructive
and nonobstructive hemodynamic forms and has become the
predominant formal term used to designate this disease.7
2.2.2. Clinical Definition and Differential Diagnosis
The generally accepted definition of HCM, the clinical en-
tity that is the subject of this guideline, is a disease state char-
acterized by unexplained LV hypertrophy associated with
nondilated ventricular chambers in the absence of another
cardiac or systemic disease that itself would be capable of
producing the magnitude of hypertrophy evident in a given
patient,6,7,9-12 with the caveat that patients who are genotype
positive may be phenotypically negative without overte158 The Journal of Thoracic and Cardiovascular Surhypertrophy.13,14 Clinically, HCM is usually recognized by
maximal LV wall thickness 15 mm, with wall thickness
of 13 to 14mmconsidered borderline, particularly in the pres-
ence of other compelling information (eg, family history of
HCM), based on echocardiography. In terms of LV wall-
thickness measurements, the literature at this time has been
largely focused on echocardiography, although cardiovascu-
lar magnetic resonance (CMR) is now used with increasing
frequency inHCM,15 andwepresume that datawith this latter
modality will increasingly emerge. In the case of children, in-
creased LV wall thickness is defined as wall thickness 2
standard deviations above the mean (z score 2) for age,
sex, or body size. However, it should be underscored that in
principle, any degree of wall thickness is compatible with
the presence of the HCMgenetic substrate and that an emerg-
ing subgroup within the broad clinical spectrum is composed
of familymemberswithdisease-causing sarcomeremutations
but without evidence of the disease phenotype (ie, LV hyper-
trophy).16-19 These individuals are usually referred to as being
‘‘genotype positive/phenotype negative’’ or as having ‘‘sub-
clinical HCM.’’ Furthermore, although a myriad of patterns
and distribution of LV hypertrophy (including diffuse and
marked) have been reported in HCM,15,20,21 about one third
of patients have largely segmental wall thickening involving
only a small portion of the left ventricle, and indeed such pa-
tients with HCM usually have normal calculated LV mass.15
The clinical diagnosis of HCM may also be buttressed by
other typical features, such as family history of the disease,
cardiac symptoms, tachyarrhythmias, or electrocardiographic
abnormalities.9,10
Differential diagnosis ofHCMandother cardiac conditions
(with LV hypertrophy) may arise, most commonly with
hypertensive heart disease and the physiologic remodeling as-
sociated with athletic training (‘‘athlete’s heart’’).22-26 These
are not uncommon clinical scenarios, and confusion between
mild morphologic expressions of HCM and other conditions
with LV hypertrophy usually arises when maximum wall
thickness is in the modest range of 13 to 15 mm. In older
patients with LV hypertrophy and a history of systemic hyper-
tension, coexistence of HCM is often a consideration. The
likelihood of HCM can be determined by identification of a
diagnostic sarcomere mutation or inferred by marked LV
thickness>25 mm and/or LVOT obstruction with systolic
anterior motion (SAM) and mitral-septal contact.
The important distinction between pathologic LV hyper-
trophy (ie, HCM) and physiologic LV hypertrophy (ie, ath-
lete’s heart) is impacted by the recognition that athletic
conditioning can produce LV, right ventricular, and left
atrial (LA) chamber enlargement, ventricular septal thick-
ening, and even aortic enlargement26 but is often resolved
by noninvasive markers, including sarcomeric mutations
or family history of HCM, LV cavity dimension (if en-
larged, favoring athlete’s heart), diastolic function, pattern
of LV hypertrophy (if unusual location or noncontiguous,gery c December 2011
Gersh et al Clinical Guidelinefavoring HCM), or short deconditioning periods in which
a decrease in wall thickness would favor athlete’s heart.22-26
Notably, it is evident that metabolic or infiltrative storage
disorders with LV hypertrophy in babies, older children,
and young adults can mimic clinically diagnosed HCM (at-
tributable to sarcomeric protein mutations), for example,
conditions such as mitochondrial disease,27,28 Fabry dis-
ease,29 or storage diseases caused by mutations in the genes
encoding the g-2-regulatory subunit of the adenosine
monophosphate (AMP)-activated protein kinase
(PRKAG2) or the X-linked lysosome-associated membrane
protein gene (LAMP2; Danon disease).30-33 Use of the term
HCM is not appropriate to describe these and other patients
with LVhypertrophy that occurs in the context of amultisys-
tem disorder such as Noonan syndrome (with craniofacial
and congenital heart malformations, as well as LV hypertro-
phy from mutations in genes of the RAS [RAt Sarcoma]
pathway14,15), or distinct cardiomyopathies such as Pompe
disease (also a glycogen storage disease II, with skeletal
muscle weakness and cardiomyopathy because of defi-
ciency of a1,4 glycosidase [acid maltase])34-38 (Figure 1).
In addition, differential diagnosis of HCM may require dis-
tinction from systemic hypertension or physiologic athlete’s
heart23 or from dilated cardiomyopathy when HCM pres-
ents in the end stage.39
2.2.3. Impact of Genetics
On the basis of the genotype-phenotype data available at
this time, HCM is regarded here as a disease entity caused
by autosomal dominant mutations in genes encoding pro-
tein components of the sarcomere and its constituent myo-
filament elements.30,40-42 Intergenetic diversity isFIGURE 1. Summary of the nomenclature that distinguishes HCM from othe
whelming evidence links the clinical diagnosis of HCM with a variety of genes
sible that in the future other nonsarcomeric (but also nonmetabolic) gene
cardiomyopathy. Modified with permission from Maron et al.12
The Journal of Thoracic and Carcompounded by considerable intragene heterogeneity,
with>1400 mutations identified among at least 8 genes.
The current weight of evidence supports the view that the
vast majority of genes and mutations responsible for clini-
cally diagnosed HCM encode proteins within and associ-
ated with the sarcomere, accounting in large measure for
those patients described in the voluminous amount of
HCM literature published over 50 years.30,40-42
In conclusion, the writing committee believes that the
most prudent recommendation for nomenclature is that hy-
pertrophic cardiomyopathy and the acronym HCM remain
a clinical diagnosis limited to those patients in whom (1)
overt disease expression (with LV hypertrophy) appears to
be confined to the heart and (2) the definitive mutation is ei-
ther one of a gene encoding proteins of the cardiac sarco-
mere or alternatively when the genotype is unresolved
using current genetic testing. Therefore, nomenclature
that describes patients as ‘‘Noonan hypertrophic cardiomy-
opathy’’ is discouraged, whereas ‘‘Noonan syndrome with
LV hypertrophy’’ or ‘‘Noonan syndrome with cardiomyop-
athy’’ is preferred.
2.2.4. Hypertrophic Cardiomyopathy Centers
The writing committee considers it important to empha-
size that HCM is a complex disease entity with a broad (and
increasing) clinical and genetic spectrum.9 Although HCM
is one of the most common forms of genetic heart disease
and relatively common in the general population,6 this dis-
ease entity is infrequent in general clinical practice, with
most cardiologists responsible for the care of only a few pa-
tients with HCM.43 This principle has led to an impetus for
establishing clinical programs of excellence—usuallyr genetic diseases associated with LV hypertrophy. *At this time the over-
encoding protein components of the cardiac sarcomere. However, it is pos-
s may prove to cause HCM. yAn example is Noonan syndrome with
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FIGURE 2. Prognosis profiles for HCM and targets for therapy. AF indi-
cates atrial fibrillation. Modified with permission from Maron et al.10
Clinical Guideline Gersh et alwithin established centers—in which cardiovascular care is
focused on the management of HCM (ie, ‘‘HCM cen-
ters’’).43,44 Such programs are stfned by cardiologists and
cardiac surgeons familiar with the contemporary manage-
ment of HCM and offer all diagnostic and treatment
options, including genetic testing and counseling, compre-
hensive transthoracic echocardiogram (TTE), CMR imag-
ing, both surgical septal myectomy and alcohol ablation,
and the management of atrial fibrillation (AF)/atrial flutter,
and ICDs. Another advantage is the potential to perform
outcomes research on large groups of patients. Although
the writing committee does not necessarily recommend
that all patients with HCM should be evaluated in such cen-
ters, nevertheless, it is the strong view that patients with this
disease may well benefit from a clinical environment with
specific expertise in HCM. The selection of patients for re-
ferral to an HCM center should be based largely on the judg-
ment of the managing cardiologist and the degree to which
he or she is comfortable advising and evaluating patients
with HCM with a particular clinical profile.3. CLINICAL COURSE AND NATURAL HISTORY,
INCLUDING ABSENCE OF COMPLICATIONS
HCM is a heterogeneous cardiac disease with a diverse
clinical presentation and course, presenting in all age
groups from infancy to the very elderly.9,10,39,45 Most
fnected individuals probably achieve a normal life expec-
tancy without disability or the necessity for major therapeu-
tic interventions.46-49 On the other hand, in some patients,
HCM is associated with disease complications that may
be profound, with the potential to result in disease progres-
sion or premature death.9,10,39,45,50,51 When the disease
does result in significant complications, there are 3 rela-
tively discrete but not mutually exclusive pathways of clin-
ical progression (Figure 2):
1. SCD due to unpredictable ventricular tachyarrhythmias,
most commonly in young asymptomatic patients<35
years of age50-59 (including competitive athletes).58,59
2. Heart failure characterized by exertional dyspnea (with
or without chest pain) that may be progressive despite
preserved systolic function and sinus rhythm, or in
a small proportion of patients, heart failure may progress
to the end stage with LV remodeling and systolic dys-
function caused by extensive myocardial scarring.39
3. AF, either paroxysmal or chronic, also associated with
various degrees of heart failure60 and an increased risk
of systemic thromboembolism and both fatal and nonfa-
tal stroke.
The natural history of HCM can be altered by a number
of therapeutic interventions: ICDs for secondary or primary
prevention of sudden death in patients with risk factors54-56;
drugs appropriate to control heart failure symptomse160 The Journal of Thoracic and Cardiovascular Sur(principally those of exertional dyspnea and chest discom-
fort),9,10 surgical septal myectomy61 or alcohol septal abla-
tion62 for progressive and drug-refractory heart failure
caused by LVOT obstruction; heart transplantation for sys-
tolic (or less frequently intractable diastolic) dysfunction
associated with severe unrelenting symptoms39; and drug
therapy or possibly radiofrequency ablation or surgical
maze procedure for AF.63-65
4. PATHOPHYSIOLOGY
The pathophysiology of HCM is complex and consists of
multiple interrelated abnormalities, including LVOT ob-
struction, diastolic dysfunction, mitral regurgitation, myo-
cardial ischemia, and arrhythmias.9,66,67 It is clinically
important to distinguish between the obstructive and nonob-
structive forms of HCM because management strategies are
largely dependent on the presence or absence of symptoms
caused by obstruction.
4.1. LVOT Obstruction
The original observations by Brock68 and Braunwald
et al3 emphasized the functional subvalvular LVOT gradi-
ent, which was highly influenced by alterations in the
load and contractility of the left ventricle. The clinical sig-
nificance of the outflow tract gradient has periodically been
controversial,69-72 but careful studies have shown defini-
tively that true mechanical obstruction to outflow does oc-
cur.66,67 For HCM, it is the peak instantaneous LV outflow
gradient rather than the mean gradient that influences treat-
ment decisions. Throughout the remainder of this document
the term gradient will be used to denote peak instantaneous
gradient. Up to one third of patients with HCMwill have ob-
struction under basal (resting) conditions (defined as gradi-
ents 30 mm Hg). Another one third or more of patients
will have labile, physiologically provoked gradients (<30
mm Hg at rest and 30 mm Hg with physiologic provoca-
tion).8 The final one third of patients will have the nonob-
structive form of HCM (gradients<30 mm Hg at rest andgery c December 2011
TABLE 2. Definitions of dynamic left ventricular outflow tract
obstruction
Hemodynamic state Conditions Outflow gradient*
Basal obstruction Rest 30 mm Hgy
Nonobstructive Rest <30 mm Hg
Physiologically provoked <30 mm Hg
Labile obstruction Rest <30 mm Hgy
Physiologically provoked 30 mm Hgy
*Either the peak instantaneous continuous wave Doppler gradient or the peak-to-peak
cardiac catheterization gradient, which are equivalent in hypertrophic cardiomyopa-
thy.73,74 yGradients 50 mm Hg either at rest or with provocation are considered the
threshold for septal reduction therapy in severely symptomatic patients.
Gersh et al Clinical Guidelinewith provocation) (Table 2). Marked gradients50 mmHg,
either at rest or with provocation, represent the conventional
threshold for surgical or percutaneous intervention if symp-
toms cannot be controlled with medications.
Obstruction causes an increase in LV systolic pressure,
which leads to a complex interplay of abnormalities includ-
ing prolongation of ventricular relaxation, elevation of LV
diastolic pressure, mitral regurgitation, myocardial ische-
mia, and a decrease in forward cardiac output.9,66,67 Out-
flow obstruction usually occurs in HCM by virtue of
mitral valve SAM and mitral-septal contact. Although the
mechanism of the outflow tract gradient in HCM was ini-
tially thought to be caused by systolic contraction of the hy-
pertrophied basal ventricular septum encroaching on the
LVOT, most recent studies emphasize that during ventricu-
lar systole, flow against the abnormally positioned mitral
valve apparatus results in drag force on a portion of the mi-
tral valve leaflets, which pushes the leaflets into the outflow
tract.66,67,75-78 Muscular obstruction can also be present in
the midcavitary region, occasionally because of hypertro-
phied papillary muscles abutting the septum79 or anomalous
papillary muscle insertion into the anterior mitral leaflet.80
Obstruction to LVoutflow is dynamic, varying with load-
ing conditions and contractility of the ventricle.3 Increased
myocardial contractility, decreased ventricular volume, or
decreased afterload increases the degree of subaortic ob-
struction. Patients may have little or no obstruction of the
LVOT at rest but can generate large LVOT gradients under
conditions such as exercise, the strain phase of the Valsalva
maneuver, or during pharmacologic provocation.66,67 There
is often large spontaneous variation in the severity of the
gradient during day-to-day activities or even with food or
alcohol intake81; exacerbation of symptoms during the post-
prandial period is common. Importantly, it has been well es-
tablished that LVOT obstruction contributes to the
debilitating heart failure–related symptoms that may occur
in HCM66,67 and is also a major determinant of outcome.45
The presence and magnitude of outflow obstruction are
usually assessed with 2-dimensional echocardiography
and continuous wave Doppler. It is a late-peaking systolic
velocity that reflects the occurrence of subaortic obstruction
late in systole, and the peak instantaneous gradient derivedThe Journal of Thoracic and Carfrom the peak velocity should be reported. If the resting out-
flow gradient is<50 mm Hg, provocative measures may be
used to ascertain if higher gradients can be elicited, prefer-
ably with physiologic exercise (stress echocardiography)
but alternatively with the Valsalva maneuver or selectively
with amyl nitrite.3,10 Provocation with dobutamine infusion
during Doppler echocardiography is no longer recommen-
ded as a strategy to induce outflow gradients in HCM. How-
ever in equivocal cases, cardiac catheterization with
isoproterenol infusionmay further aid in eliciting a provoca-
ble gradient.82 Otherwise, routine invasive cardiac catheter-
ization to document outflow gradients is necessary only
when there are discordant data from Doppler echocardiog-
raphy and the physical examination.10 The peak-to-peak
gradient obtained with catheterization most closely approx-
imates the peak instantaneous gradient by continuous wave
Doppler echocardiography.73,74
4.2. Diastolic Dysfunction
Diastolic dysfunction arising from multiple factors is
a major pathophysiologic abnormality in HCM that ulti-
mately fnects both ventricular relaxation and chamber stiff-
ness.66,67,83 Impairment of ventricular relaxation results
from the systolic contraction load caused by outflow tract
obstruction, nonuniformity of ventricular contraction and
relaxation, and delayed inactivation caused by abnormal in-
tracellular calcium reuptake. Severe hypertrophy of the
myocardium results in an increase in chamber stiffness. Dif-
fuse myocardial ischemia may further fnect both relaxation
and chamber stiffness. A compensatory increase in the con-
tribution of late diastolic filling during atrial systole is asso-
ciated with these alterations.84 With exercise or any other
type of catecholamine stimulation, the decrease in diastolic
filling period as well as myocardial ischemia will further
lead to severe abnormalities of diastolic filling of the heart,
with chest pain and/or an increase in pulmonary venous
pressure causing dyspnea.
4.3. Myocardial Ischemia
Severe myocardial ischemia and even infarction may oc-
cur in HCM.85,86 The myocardial ischemia is frequently un-
related to the atherosclerotic epicardial coronary artery
disease (CAD) but is caused by supply–demand mismatch.
Patients with HCM of any age have increased oxygen de-
mand caused by the hypertrophy and adverse loading con-
ditions. They also have compromised coronary blood flow
to the LV myocardium because of intramural arterioles
with thickened walls attributable to medial hypertrophy as-
sociated with luminal narrowing.87
4.4. Autonomic Dysfunction
During exercise, approximately 25% of patients with
HCM have an abnormal blood pressure response defined by
either a failure of systolic blood pressure to rise>20 mmdiovascular Surgery c Volume 142, Number 6 e161
Clinical Guideline Gersh et alHg or a fall in systolic blood pressure.88,89 The presence of
this finding is associatedwith a poorer prognosis.89,90 This in-
ability to augment and sustain systolic blood pressure during
exercise is caused by either the dynamic LVOTobstruction or
systemic vasodilatation during exercise. It is speculated that
autonomic dysregulation88 is present in patients with HCM
and that the fall in blood pressure associatedwith bradycardia
may be an abnormal reflex response to obstruction.4.5. Mitral Regurgitation
Mitral regurgitation is common in patients with LVOT
obstruction and may play a primary role in producing
symptoms of dyspnea. The temporal sequence of events
of eject-obstruct-leak supports the concept that the mitral
regurgitation in most patients is a secondary phenome-
non.66,67,91 The mitral regurgitation is usually caused by
the distortion of the mitral valve apparatus from the SAM
secondary to the LVOT obstruction. The jet of mitral regur-
gitation is directed laterally and posteriorly and predomi-
nates during mid and late systole. An anteriorly directed
jet should suggest an intrinsic abnormality of the mitral
valve. If the mitral regurgitation is caused by distortion of
leaflet motion by SAM of the mitral valve, the severity of
themitral regurgitationmay be proportional to the LVOTob-
struction in some patients. Changes in ventricular load and
contractility that fnect the severity of outflow tract obstruc-
tion similarly fnect the degree of mitral regurgitation. It is
important to identify patients with additional intrinsic dis-
ease of the mitral valve apparatus (prolapse or flail), because
this finding influences subsequent treatment options.925. DIAGNOSIS
The clinical diagnosis of HCM is conventionally made
with cardiac imaging, at present most commonly with
2-dimensional echocardiography and increasingly with
CMR. Morphologic diagnosis is based on the presence of
a hypertrophied and nondilated left ventricle in the absence
of another cardiac or systemic disease capable of producing
the magnitude of hypertrophy evident in a patient (usually
15 mm in adults or the equivalent relative to body surface
area in children). Genetic testing, which is now commer-
cially available, is a powerful strategy for definitive diagno-
sis of fnected genetic status and is currently used most
effectively in the identification of fnected relatives in fami-
lies known to have HCM.5.1. Genetic Testing Strategies/Family Screening—
Recommendations
Class I
1. Evaluation of familial inheritance and genetic counseling is recom-
mended as part of the assessment of patients with HCM.17,31,93-96
(Level of Evidence: B)e162 The Journal of Thoracic and Cardiovascular Sur2. Patients who undergo genetic testing should also undergo counsel-
ing by someone knowledgeable in the genetics of cardiovascular dis-
ease so that results and their clinical significance can be
appropriately reviewed with the patient.97-101 (Level of Evidence: B)
3. Screening (clinical, with or without genetic testing) is recommended
in first-degree relatives of patients with HCM.17,31,93,94,96,102,103
(Level of Evidence: B)
4. Genetic testing for HCM and other genetic causes of unexplained
cardiac hypertrophy is recommended in patients with an atypical
clinical presentation of HCM or when another genetic condition is
suspected to be the cause.104-106 (Level of Evidence: B)
Class IIa
1. Genetic testing is reasonable in the index patient to facilitate the
identification of first-degree family members at risk for developing
HCM.17,95,102 (Level of Evidence: B)
Class IIb
1. The usefulness of genetic testing in the assessment of risk of SCD in
HCM is uncertain.107,108 (Level of Evidence: B)
Class III: No Benefit
1. Genetic testing is not indicated in relatives when the index patient
does not have a definitive pathogenic mutation.17,31,93-96,109 (Level
of Evidence: B)
2. Ongoing clinical screening is not indicated in genotype-negative
relatives in families with HCM.109-112 (Level of Evidence: B)
See Online Data Supplement 1 for additional data re-
garding genetic testing strategies/family screening.
HCM is caused by an autosomal dominant mutation
in genes that encode sarcomere proteins or sarcomere-
associated proteins. The most vigorous evidence indicates
that 8 genes are known to definitively cause HCM: beta my-
osin heavy chain, myosin binding protein C, troponin T, tro-
ponin I, alpha tropomyosin, actin, regulatory light chain,
and essential light chain.11,12,30,40-42 In addition, actinin
and myozenin are associated with less definitive evidence
for causing HCM. At this time there is inconclusive evi-
dence to support other genes causing HCM,94,96,113,114 but
research is ongoing and other genetic causes may be identi-
fied.93,115 A single mutation in 1 of the 2 alleles (or copies)
of a gene is sufficient to cause HCM; however, 5% of pa-
tients with HCM have2 mutations in the same gene or dif-
ferent genes.110,116
Genetic and/or clinical screening of all first-degree fam-
ily members of patients with HCM is important to identify
those with unrecognized disease. On the basis of family his-
tory, clinical screening, and pedigree analyses, the pattern
of inheritance is ascertained to identify and counsel rela-
tives at risk.101 Because familial HCM is a dominant disor-
der, the risk that an fnected patient will transmit disease to
each offspring is 50%. When a pathogenic mutation is iden-
tified in an index patient, the genetic status of each family
member can be readily ascertained. Because HCMgery c December 2011
Gersh et al Clinical Guidelinemutations are highly penetrant, a mutation conveys substan-
tial (>95%) risk over a lifetime for developing clinical and/
or phenotypic evidence of HCM.94,96,113,114
Genetic counseling before genetic testing will increase
understanding of the medical and familial implications of
test results, enabling informed decision making about po-
tential risks and benefits.98,99 Genetic counseling can also
reduce potential psychologic responses to learning one’s
mutation status.4,101 Even when genetic testing is not under-
taken, genetic counseling about the potential for familial
transmission of HCM is medically important.
The occurrence of HCM can be isolated or sporadic, but
the frequency of sporadic HCM is unresolved. Sporadic
HCM can reflect an inaccurate family history, incomplete
penetrance (absence of clinical expression despite the pres-
ence of a mutation) in family members, or a de novo (new)
mutation that can initiate new familial disease.93,115
Because unrelated patients with HCM will have different
mutations, a comprehensive sequence-based analysis of all
HCM genes is necessary to define the pathogenic (eg,
disease-causing) mutation in an index patient. Experienced
clinical laboratories identify the pathogenic HCMmutation
in approximately 60% to 70% of patients with a positive
family history and approximately 10% to 50% of patients
without a family history.93,102 Genetic testing may identify
a pathogenic mutation (eg, analysis defines a sequence
variant known to cause HCM) or a ‘‘likely pathogenic’’ mu-
tation, aDNAvariant thatwas previouslyunknown as a cause
of HCM but has molecular characteristics that are similar to
recognized HCM mutations. Genetic testing may also iden-
tify ‘‘variants of uncertain significance.’’ This term indicates
that the nucleotide change is not commonly recognized to be
variable (or polymorphic) in the general population and that
somemolecular characteristics of the variant suggest delete-
rious consequences (similar to all pathogenic mutations).
Genetic analyses of familymembers can help establish or re-
fute the causality of ‘‘likely pathogenic’’ and ‘‘variants of
uncertain significance.’’ When a variant occurs in multiple
clinically fnected family members but is absent from clini-
cally unaffected adult family members, the likelihood for
pathogenicity increases. In contrast, when a variant occurs
in multiple clinically unaffected adult family members, the
likelihood for pathogenicity is low.
Adult patients with HCM and an established pathogenic
mutation have increased risk for the combined endpoints of
cardiovascular death, nonfatal stroke, or progression to New
York Heart Association (NYHA) functional class III or IV
compared with patients with HCM in whom no mutation
is identified.103 Studies suggest that the presence of>1
HCM-associated sarcomere mutation is associated with
greater severity of disease.110,111,117,118
When genetic testing reveals a mutation in the index pa-
tient, ascertainment of genetic status in first-degree relatives
can be predictive of risk for developing HCM.105 GeneticThe Journal of Thoracic and Carcounseling should precede genetic testing of family mem-
bers.101 Relatives with overt HCM will have the same path-
ogenic HCM mutation as the index patient. Pathogenic
mutations may also be identified in other relatives with un-
known clinical status. These mutation carriers should be
evaluated by physical examination, electrocardiography,
and 2-dimensional echocardiography, and if HCM is identi-
fied, these individuals should undergo risk stratification
(Section 6.3.1). Mutation carriers without evidence of
HCM (genotype positive/phenotype negative) are at consid-
erable risk for future development of HCM, and guidelines
to evaluate these individuals are discussed below.13,14
Mutation-negative family members and their descendents
have no risk for developing HCM and do not need further
evaluation. Information from genotyping may help define
clinical manifestations and outcomes in specific families
with HCM.94-96,105,107-109,119
When genetic testing is not performed or a mutation is
not identified in the index patient, clinical screening of all
first-degree family members is important to identify those
with unrecognized HCM. Offspring of unaffected individ-
uals do not warrant clinical screening unless prompted by
unexpected signs or symptoms. For more information on
screening intervals, see Section 5.3.1.5.1.1. Genotype-Positive/Phenotype-Negative Patients—
Recommendation
Class I
1. In individuals with pathogenic mutations who do not express the
HCM phenotype, it is recommended to perform serial electrocardio-
gram (ECG), TTE, and clinical assessment at periodic intervals
(12 to 18 months in children and adolescents and about every 5 years
in adults), based on the patient’s age and change in clinical
status.16,120-122 (Level of Evidence: B)
Genetic screening of first-degree relatives of an index
patient with HCM can reveal typically young family
members with a mutation (genotype positive) but with-
out cardiac hypertrophy (phenotype negative) (Table
3).13,14,17,105,123,124 As the clinical expression of HCM
usually increases with age, clinical screening (by physical
examination, electrocardiography, and 2-dimensional
echocardiography or CMR) of genotype-positive/
phenotype-negative individuals is also recommended at
the intervals indicated below. Electrocardiographic abnor-
malities, increased ejection fraction (EF), and delayed
myocardial relaxation can precede the onset of hypertro-
phy.17,124 When abnormal, these parameters can indicate
early emergence of clinical disease. Information about
risk of SCD is limited.13,14,121,122
When family history indicates a high risk for SCD, peri-
odic assessment of arrhythmias (by exercise stress testing or
Holter monitoring) in genotype-positive/phenotype-
negative individuals may be appropriate. Decisions aboutdiovascular Surgery c Volume 142, Number 6 e163
TABLE 3. Proposed clinical screening strategies with
echocardiography (and 12-lead ECG) for detection of hypertrophic
cardiomyopathy with left ventricular hypertrophy in families*
Age<12 y
Optional unless
Malignant family history of premature death from HCM or other
adverse complications
Patient is a competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early LV hypertrophy
Age 12 to 18–21 yy
Every 12–18 mo
Age>18–21 y
At onset of symptoms or at least every 5 y. More frequent intervals are
appropriate in families with a malignant clinical course or late-onset
HCM.
ECG, Electrocardiogram; HCM, hypertrophic cardiomyopathy; LV, left ventricular.
*When pathologic mutations are not identified or genetic testing is either ambiguous
or not performed. yAge range takes into consideration individual variability in achiev-
ing physical maturity and in some patients may justify screening at an earlier age. Ini-
tial evaluation should occur no later than early pubescence.125Adapted with
permission from Maron et al.126
Clinical Guideline Gersh et alparticipation in competitive athletics must be resolved on
a case-by-case basis with the patient and family fully in-
formed about the potential risks13 (Section 6.3.3).5.2. Electrocardiography—Recommendations
Class I
1. A 12-lead ECG is recommended in the initial evaluation of patients
with HCM. (Level of Evidence: C)
2. Twenty-four–hour ambulatory (Holter) electrocardiographic
monitoring is recommended in the initial evaluation of patients
with HCM to detect ventricular tachycardia (VT) and identify
patients who may be candidates for ICD therapy.10,127-129 (Level
of Evidence: B)
3. Twenty-four–hour ambulatory (Holter) electrocardiographic mon-
itoring or event recording is recommended in patients with HCM
who develop palpitations or lightheadedness.10,127,128 (Level of Evi-
dence: B)
4. A repeat ECG is recommended for patients withHCMwhen there is
worsening of symptoms. (Level of Evidence: C)
5. A 12-lead ECG is recommended every 12 to 18 months as a compo-
nent of the screening algorithm for adolescent first-degree relatives
of patients with HCM who have no evidence of hypertrophy on
echocardiography. (Level of Evidence: C)
6. A 12-lead ECG is recommended as a component of the screening al-
gorithm for first-degree relatives of patients with HCM. (Level of
Evidence: C)
Class IIa
1. Twenty-four–hour ambulatory (Holter) electrocardiographic mon-
itoring, repeated every 1 to 2 years, is reasonable in patients with
HCM who have no previous evidence of VT to identify patients
who may be candidates for ICD therapy.129 (Level of Evidence: C)
2. Annual 12-lead ECGs are reasonable in patients with known HCM
who are clinically stable to evaluate for asymptomatic changes in
conduction or rhythm (ie, AF). (Level of Evidence: C)e164 The Journal of Thoracic and Cardiovascular SurClass IIb
1. Twenty-four–hour ambulatory (Holter) electrocardiographic mon-
itoringmight be considered in adults withHCM to assess for asymp-
tomatic paroxysmal AF/atrial flutter. (Level of Evidence: C)
The 12-lead ECG is useful largely for raising the suspi-
cion of HCM in family members without LV hypertrophy
and in identifying patterns such as Wolff-Parkinson-White
syndrome, which may suggest certain phenocopies of
HCM.9,130-132 In addition, patterns mimicking myocardial
infarction may provide evidence of the diagnosis and may
be present in young individuals before there is manifest ev-
idence of wall thickening on echocardiography.10,132,133
The 12-lead ECG is abnormal in 75% to 95% of patients
with HCM.9,131,132 These abnormalities do not correlate
with severity or pattern of hypertrophy as determined by
echocardiography.
Ambulatory electrocardiographic monitoring for detec-
tion of ventricular tachyarrhythmias plays an important
role in risk stratification of asymptomatic or symptomatic
patients with HCM because episodes of nonsustained ven-
tricular tachycardia (NSVT) identify patients at signifi-
cantly higher risk of subsequent SCD.9,10,132-134 It is
reasonable to perform serial ambulatory electrocardio-
graphic monitoring on an annual basis or every 2 years in
patients who are stable and do not manifest arrhythmias
on baseline 12-lead ECG and Holter monitoring and who
do not have ICDs.
The yield of ambulatory electrocardiographic monitoring
for detection of AF or atrial flutter in patients who were pre-
viously asymptomatic without arrhythmias is unknown.5.3. Imaging
5.3.1. Echocardiography—Recommendations
Class I
1. ATTE is recommended in the initial evaluation of all patients with
suspected HCM.9,20,66,67,135-138 (Level of Evidence: B)
2. ATTE is recommended as a component of the screening algorithm
for family members of patients with HCM unless the family mem-
ber is genotype negative in a family with known definitive muta-
tions.41,126,139,140 (Level of Evidence: B)
3. Periodic (12 to 18 months) TTE screening is recommended for chil-
dren of patients with HCM, starting by age 12 years or earlier if
a growth spurt or signs of puberty are evident and/or when there
are plans for engaging in intense competitive sports or there is a fam-
ily history of SCD.126,141 (Level of Evidence: C)
4. Repeat TTE is recommended for the evaluation of patients with
HCM with a change in clinical status or new cardiovascular
event.39,45,57,142-145 (Level of Evidence: B)
5. A transesophageal echocardiogram (TEE) is recommended for the
intraoperative guidance of surgical myectomy.146-148 (Level of Evi-
dence: B)
6. TTE or TEE with intracoronary contrast injection of the candi-
date’s septal perforator(s) is recommended for the intraprocedural
guidance of alcohol septal ablation.62,149-151 (Level of Evidence: B)gery c December 2011
Gersh et al Clinical Guideline7. TTE should be used to evaluate the effects of surgical myectomy or
alcohol septal ablation for obstructive HCM.61,62,152-156 (Level
of Evidence: C)Class IIa
1. TTE studies performed every 1 to 2 years can be useful in the serial
evaluation of symptomatically stable patients with HCM to assess
the degree of myocardial hypertrophy, dynamic obstruction, and
myocardial function.20,67,136 (Level of Evidence: C)
2. Exercise TTE can be useful in the detection and quantification of
dynamic LVOT obstruction in the absence of resting outflow tract
obstruction in patients with HCM.8,45,143,145,157 (Level of Evidence:
B)
3. TEE can be useful if TTE is inconclusive for clinical decision mak-
ing about medical therapy and in situations such as planning for
myectomy, exclusion of subaortic membrane or mitral regurgita-
tion secondary to structural abnormalities of the mitral valve appa-
ratus, or in assessment for the feasibility of alcohol septal
ablation.146-148 (Level of Evidence: C)
4. TTE combinedwith the injection of an intravenous contrast agent is
reasonable if the diagnosis of apical HCM or apical infarction or se-
verity of hypertrophy is in doubt, particularly when other imaging
modalities such as CMR are not readily available, not diagnostic, or
are contraindicated. (Level of Evidence: C)
5. Serial TTE studies are reasonable for clinically unaffected patients
who have a first-degree relative with HCM when genetic status is
unknown. Such follow-up may be considered every 12 to 18 months
for children or adolescents fromhigh-risk families and every 5 years
for adult family members.41,126,140,141 (Level of Evidence: C)
Class III: No Benefit
1. TTE studies should not be performedmore frequently than every 12
months in patients with HCM when it is unlikely that any changes
have occurred that would have an impact on clinical decision mak-
ing. (Level of Evidence: C)
2. Routine TEE and/or contrast echocardiography is not recommen-
dedwhen TTE images are diagnostic of HCMand/or there is no sus-
picion of fixed obstruction or intrinsicmitral valve pathology. (Level
of Evidence: C)
Comprehensive TTE and Doppler studies should be per-
formed in the initial evaluation of all patients with sus-
pected HCM, as well as during follow-up, particularly
when there is a change in cardiovascular symptoms or an
event. Echocardiographic studies are essential for establish-
ing the diagnosis and the nature and extent of hypertrophy,
defining prognosis, and guiding management.9,20,66,67,
135-138 Although septal thickness 15 mm is commonly
used to identify HCM, one must be aware of the potential
confusion with secondary hypertrophy attributable to aortic
valve or discrete subaortic stenosis, systemic hypertension,
amyloidosis, and other genetic phenocopies such as Fabry
disease.158 In fnected family members with HCM, the de-
gree of hypertrophy may be below the usual diagnostic
threshold of 15 mm LV wall thickness, and indeed,
some patients carry an HCM-definitive mutation without
hypertrophy.
It has been suggested that identification of morphologic
subtypes of LV hypertrophy, namely apical hypertrophy159The Journal of Thoracic and Caror septal hypertrophy with reverse or neutral curvature, or
sigmoid shape,160 has implications for the likelihood of
detection of myofilament mutations and prognosis.139 How-
ever, there is no recognized relationship between the pattern
or distribution of LV hypertrophy and clinical course or out-
come. Nevertheless, documentation of the extent of hypertro-
phy is important because there is a relatively linear association
between maximal wall thickness and sudden death, with
highest risk in patients with wall thickness30 mm.161
The presence of dynamic LVOT obstruction is related to
symptomatic status, as well as development of AF, embolic
complications, and death.45,57,142-145 Continuous wave
Doppler studies can accurately quantitate the LVOT gradient
and determine the response to pharmacologic157 and inter-
ventional therapy. Amyl nitrite can be used to provoke echo-
cardiographically documented gradients when available and
in laboratories with expertise and has the advantage of being
capable of being integrated into a single examination. The
correlation between pharmacologic and physiologic exercise
provocation of outflow gradients is unresolved. Care must be
taken to correctly identify the site of obstruction, distinguish
the Doppler spectral profile from cavity obliteration, and
avoid contamination of the signal bymitral regurgitation.Al-
though many patients have dynamic LVOT obstruction at
rest, a significant number will have new or higher gradients
after the Valsalva maneuver, inhalation of amyl nitrite, or
during provocative exercise.8 In HCM, it is the peak instan-
taneous LVOT velocity, usually caused by SAM, that should
be used to determine the maximum gradient, using the
modified Bernoulli formula (Table 2).
Systolic function, as assessed by wall motion and EF, is
usually normal in patients with HCM; however, the devel-
opment of systolic dysfunction heralds the risk of progres-
sive and irreversible heart failure, which may result in heart
transplantation or death.39 The importance of diastolic dys-
function in HCM has led to an extensive search for nonin-
vasive methods to quantify its severity. With the complex
interplay of factors causing diastolic dysfunction in HCM,
no single noninvasivemeasure has been demonstrated as su-
perior.162,163 LA volume may provide a long-term indica-
tion of the effects of chronically elevated filling pressures
in patients with HCM.164-166 Patients with HCM and a max-
imal LAvolume index34 mL/m2 have a higher incidence
of abnormal diastolic filling, a higher mitral inflow/annular
velocity (E/e0) ratio, a higher calculated LA pressure, and
less favorable outcome.164,166 Moreover, LAvolumetric re-
modeling predicts exercise capacity in nonobstructive HCM
and thus may reflect chronic LV diastolic burden indepen-
dent of LVOT obstruction. The more recent use of myocar-
dial deformation measurements to quantify strain
parameters, torsion, and dyssynchrony has detected abnor-
malities in systolic performance, especially longitudinal
strain and twist.167-171 These methods have also shown
promise in better quantifying abnormalities in earlydiovascular Surgery c Volume 142, Number 6 e165
Clinical Guideline Gersh et alrelaxation and elevation of filling pressures.172 They
may also be useful in distinguishing HCM from other
forms of hypertrophy,173 as well as detecting preclinical
disease.17,19,174
Echocardiographic studies are useful in patients with
LVOT obstruction who fail to respond to medical therapy
and who undergo invasive intervention.61,146-148,155,175,176
TEE studies, performed before arrival in the operating suite
for surgical septal myectomy (and intraoperative TEE), can
determine the length and extent of myectomy required,
evaluate the presence and severity of mitral regurgitation in-
dependent of obstruction, and identify the presence of abnor-
mal papillary muscle architecture.146-148,155,176 Following
myectomy, postbypass intraoperative TEE studies can
confirm the adequacy of myectomy and quantitate residual
gradients, severity of mitral and aortic regurgitation, ventric-
ular function, and development of a ventricular septal de-
fect.146-148,155,176 When the myectomy is inadequate based
on TEE study, surgical revision can be considered.
Intraprocedural echocardiographic studies should be
routinely performed during alcohol septal ablation proce-
dures.62,149-152,156,177 Contrast-enhanced echocardio-
graphic studies with intracoronary injection of the
candidate coronary septal perforator(s) are important in
determining the perfusion bed supplied by the septal perfo-
rator so that only an appropriate site and degree of myocar-
dium is infarcted and complications avoided.149-151 After
alcohol septal ablation there may be an early recurrence
in the LVOT gradient a few days after the procedure, with
subsequent reduction over 6 to 12 months.152,156
It should be recognized that in some patients TTE studies
may be limited by image quality, and other investigations, in-
cluding CMR, should be performed. In addition, TEE may
detect the presence of subaortic membrane causing fixed ob-
struction with or without coexisting dynamic obstruction. In
patients with the apical variant of HCM, the diagnosis is
missed by echocardiographic studies in about 10% of pa-
tients,159 and the use of peripheral injection of an echocardio-
graphic contrast agent, as well as CMR, may be useful in
establishing the diagnosis. Similarly, a subset of patients
with HCM may have an apical LV aneurysm associated
with normal epicardial coronary arteries,159 which is usually
best visualized with CMR. TEE studies may be helpful in
some patients, particularly when the cause and severity of
mitral regurgitation are uncertain.147,148
5.3.2. Stress Testing—Recommendations
Class IIa
1. Treadmill exercise testing is reasonable to determine functional ca-
pacity and response to therapy in patients with HCM. (Level of Ev-
idence: C)
2. Treadmill testing with monitoring of an ECG and blood pressure is
reasonable for SCD risk stratification in patients with HCM.89,90,178
(Level of Evidence: B)e166 The Journal of Thoracic and Cardiovascular Sur3. In patients with HCM who do not have a resting peak instanta-
neous gradient of greater than or equal to 50 mm Hg, exercise
echocardiography is reasonable for the detection and quantifica-
tion of exercise-induced dynamic LVOT obstruction.8,88-90 (Level
of Evidence: B)
Exercise testing with monitoring of ECG and cuff blood
pressure is helpful in risk assessment of patients with HCM,
because abnormal blood pressure responses to exercise
(defined as either a failure to increase by at least 20 mm
Hg or a drop of at least 20 mm Hg during effort) has been
demonstrated to be 1 factor associated with risk of
SCD.9,10,89,90,134,178 A hypotensive blood pressure response
was defined as either an initial increase in systolic blood
pressure with a subsequent fall by peak exercise of>20
mm Hg compared with peak blood pressure value8,90 or
a continuous decrease in systolic blood pressure of>20
mm Hg throughout the exercise test when compared with
baseline. A flat response was defined by a change in systolic
blood pressure during the whole exercise period of<20 mm
Hg compared with the resting systolic blood pressure. Most
published studies examining exercise blood pressure re-
sponse use symptom-limited treadmill exercise testing
with a Bruce protocol,89,178 whereas others use symptom-
limited bicycle ergometry, with 25-W increments in
3-minute stages.90
Combining exercise testing with Doppler echocardiogra-
phy is also useful for determining the presence of physio-
logically provocable LVOT obstruction and is particularly
helpful in patients with symptoms during routine physical
activities who do not manifest outflow obstruction at rest.8
Stress testing modalities include either bicycle, treadmill
using the Bruce protocol, or cardiopulmonary (metabolic)
testing, with measurement of gradient either during or im-
mediately after exercise.8 In symptomatic patients with
a peak resting gradient of<50 mm Hg, it is helpful to per-
form exercise echocardiography to determine if a significant
exercise-induced gradient (or increase in mitral regurgita-
tion) or augmentation thereof is present.
The role of metabolic stress testing (ie, determination of
maximum oxygen consumption) in the routine evaluation of
patients with HCM remains to be decided, particularly with
regard to clinical outcome, but in individual patients this
test may be helpful in providing a more precise assessment
of functional capacity.1795.3.3. Cardiac Magnetic Resonance—Recommendations
Class I
1. CMR imaging is indicated in patients with suspected HCM when
echocardiography is inconclusive for diagnosis.180,181 (Level of
Evidence: B)
2. CMR imaging is indicated in patients with knownHCMwhen addi-
tional information that may have an impact on management or de-
cision making regarding invasive management, such as magnitude
and distribution of hypertrophy or anatomy of the mitral valvegery c December 2011
Gersh et al Clinical Guidelineapparatus or papillarymuscles, is not adequately definedwith echo-
cardiography.15,180-183 (Level of Evidence: B)
Class IIa
1. CMR imaging is reasonable in patients with HCM to define apical
hypertrophy and/or aneurysm if echocardiography is inconclu-
sive.180,182 (Level of Evidence: B)
Class IIb
1. In selected patients with known HCM, when SCD risk stratification
is inconclusive after documentation of the conventional risk factors
(Section 6.3.1), CMR imaging with assessment of late gadolinium
enhancement (LGE) may be considered in resolving clinical deci-
sion making.184-188 (Level of Evidence: C)
2. CMR imaging may be considered in patients with LV hypertrophy
and the suspicion of alternative diagnoses to HCM, including car-
diac amyloidosis, Fabry disease, and genetic phenocopies such as
LAMP2 cardiomyopathy.189-191 (Level of Evidence: C)
There have been significant advances in CMR in recent
years, and most centers now have access to this advanced
imaging technique. Compared with other noninvasive car-
diac imaging modalities, CMR provides superior spatial
resolution with sharp contrast between blood and myocar-
dium, as well as complete tomographic imaging of the en-
tire LV myocardium and therefore the opportunity to
more accurately characterize the presence, distribution,
and extent of LV hypertrophy in HCM. Because of the tech-
nical complexity of CMR imaging, data from the published
literature are only generalizable if imaging is performed
with high technical quality by experienced operators and in-
terpreted by well-trained and experienced readers.
The primary role for CMR in patients with HCM is
clarification of diagnosis and phenotype. Advances in
2-dimensional echocardiography have demonstrated the
heterogeneity of the hypertrophic phenotype in patients
with HCM, particularly with regard to distribution of LV
hypertrophy and mechanisms of outflow obstruc-
tion.8-10,15,21,72,192 However, there remain patients in
whom the diagnosis of HCM is suspected but the echocar-
diogram is inconclusive, mostly because of suboptimal im-
aging from poor acoustic windows or when hypertrophy is
localized to regions of the LV myocardium not well visual-
ized by echocardiography.15 In 1 study, 6% of patients with
suspected HCM were identified with increased LV wall
thickness (predominantly in the anterolateral wall) by
CMR but not by echocardiography.15,181,183 In addition, in
patients with HCM in whom hypertrophy is predominantly
confined to the apex (ie, apical HCM), increased wall thick-
ness in this region of the LVmyocardiummay be difficult to
visualize clearly with echocardiography but can be well
seen with CMR.180,182 Similarly, in the subgroup of patients
with HCM who develop apical aneurysms, CMR can more
readily detect the presence of an aneurysm (particularly
when small) compared with noncontrast echocardiogra-
phy.182 Identification of the end-stage phenotype andThe Journal of Thoracic and Carparticularly an apical aneurysm has implications for man-
agement in that an ICD may be indicated and anticoagula-
tion could be considered, based on the morphologic
appearance of the aneurysm. In addition to diagnosis, the
extent of maximal LV wall thickening may be underesti-
mated by echocardiography compared with CMR, particu-
larly when this region involves the anterolateral wall.15,183
This observation is related to the limitation of
2-dimensional echocardiography in differentiating the epi-
cardial border of the lateral LV free wall from thoracic
parenchyma, allowing significant underestimation of wall
thickness compared with CMR, which provides more reli-
able definition of the epicardial border. Accurate character-
ization of the HCM phenotype by CMR may also be useful
in management decisions for invasive therapies (septal
myectomy or alcohol septal ablation) by more precisely de-
fining the location and magnitude of hypertrophy, as well as
characterizing the mitral and submitral apparatus and pap-
illary muscles.193,194
The opportunity for contrast-enhanced CMR with LGE
to identify areas of myocardial fibrosis in patients with
HCM has been the subject of a growing area of the litera-
ture.185-187,195,196 The extent and transmural distribution
of areas of infarction can be quantitatively defined in pa-
tients with CAD.197 Many studies have now documented
that approximately half of patients with HCM have LGE
suggestive of areas of fibrosis that in some patients may oc-
cupy a substantial volume of LV myocardium (ie, on aver-
age, 10% of the LV wall).185,195 Although patients with the
end-stage phenotype almost universally demonstrate such
findings,39 patients with HCMwith preserved systolic func-
tion may also have areas of LGE.185-187 Importantly, pa-
tients with HCM with evidence of LGE on CMR imaging
tend to have more markers of risk of SCD, such as NSVT
on Holter monitoring, than patients without LGE.184,186
It is a plausible and attractive concept that areas of LGE
(ie, probably largely replacement myocardial fibrosis)
could represent a substrate for the generation of malignant
ventricular tachyarrhythmias in HCM and thus a marker
for risk of SCD. Several studies have addressed this issue
and have reported either trends in such a direction or signif-
icant associations between the presence of LGE (not extent)
and cardiac outcome events.187,198 However, there is insuf-
ficient evidence at this time to support a significant associ-
ation between the extent of LGE and outcome. Larger
studies with longer follow-up and more events with greater
statistical power are needed to fully characterize whether
the finding of LGE can be considered a specific risk marker
for SCD to the same degree as currently accepted markers
such as family history of SCD or extreme LVwall thickness.
Nonetheless, the present cross-sectional and short-term fol-
low-up data would support a potential role of contrast-
enhanced CMR (with evidence of LGE) as an arbitrator to
consider in clinical decision making for primary preventiondiovascular Surgery c Volume 142, Number 6 e167
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uncertain after assessment of conventional risk
factors.185,186
In some patients with LV hypertrophy, CMR imaging can
depict patterns of LGE that may suggest an alternative diag-
nosis. In patients with Anderson-Fabry disease, it has been
reported that approximately half have LGE localized to the
mid-myocardial portion of the basal inferolateral wall, spar-
ing the subendocardium,191 a location and distribution of
LGE that may help distinguish this disease from other forms
of nonischemic cardiomyopathies such as HCM.189 Patterns
of LGE in HCM are heterogeneous, may occur commonly
in either the ventricular septum or LV free wall, and usually
involve segments of the chamber that are most hypertro-
phied and do not conform to particular coronary arterial
distributions.185
Among patients with LV hypertrophy caused by cardiac
amyloidosis, it has been reported that approximately 70%
demonstrate a pattern of global subendocardial gadolinium
enhancement, a pattern of enhancement not usually seen in
patients with HCM.190 These data suggest that gadolinium-
enhanced CMR imaging may be useful in select cases to as-
sist a clinician in the differential diagnosis of a patient with
LV hypertrophy.5.4. Detection of Concomitant Coronary Disease—
Recommendations
Class I
1. Coronary arteriography (invasive or computed tomographic imag-
ing) is indicated in patients with HCM with chest discomfort who
have an intermediate to high likelihood of CAD when the identifica-
tion of concomitant CADwill changemanagement strategies. (Level
of Evidence: C)
Class IIa
1. Assessment of coronary anatomy with computed tomographic angi-
ography (CTA) is reasonable for patients with HCM with chest dis-
comfort and a low likelihood of CAD to assess for possible
concomitant CAD. (Level of Evidence: C)
2. Assessment of ischemia or perfusion abnormalities suggestive of
CAD with single photon emission computed tomography (SPECT)
or positron emission tomography (PET) myocardial perfusion im-
aging (MPI; because of excellent negative predictive value), is rea-
sonable in patients with HCM with chest discomfort and a low
likelihood of CAD to rule out possible concomitant CAD. (Level of
Evidence: C)
Class III: No Benefit
1. Routine SPECT MPI or stress echocardiography is not indicated
for detection of ‘‘silent’’ CAD-related ischemia in patients with
HCM who are asymptomatic. (Level of Evidence: C)
2. Assessment for the presence of blunted flow reserve (microvascular
ischemia) using quantitative myocardial blood flow measurements
by PET is not indicated for the assessment of prognosis in patients
with HCM. (Level of Evidence: C)e168 The Journal of Thoracic and Cardiovascular SurChest discomfort is a common symptom in patients with
HCM. A key management issue revolves around whether
the discomfort may be caused by concomitant epicardial
obstructive CAD with inducible ischemia, a consequence
of microvascular dysfunction, or a combination of these
factors.9 The concomitant presence of CAD, particularly
if severe, in patients with HCM identifies a higher risk for
adverse outcomes and patients who are potential candidates
for revascularization.199,200 Moreover, in considering man-
agement options such as alcohol septal ablation or septal
myectomy for patients with highly symptomatic HCM,
knowledge of coronary anatomy is an important factor in-
forming the decision.
Myocardial bridging (ie, tunneling) is a clinical feature in
patients with HCM that may be associated with myocardial
ischemia in the absence of epicardial coronary stenosis. In
myocardial bridging, a segment of the left anterior descend-
ing coronary artery courses within the myocardium. The
prevalence of myocardial bridging varies based on the
type of investigation. In a recent autopsy-based study in pa-
tients with HCM, bridging was evident in 40% of hearts,201
whereas angiographic prevalence in HCM is reported to be
15%.202 Myocardial bridges are a frequent component of
phenotypically expressed HCM and more common than
in other disorders with or without LV hypertrophy. Al-
though it has been suggested that ischemia secondary to
bridging could be a potential mechanism for sudden death
in patients with HCM,203 there is no consistent evidence
to support this hypothesis in either adults or children.202,204
However, the possibility that coronary arterial bridges could
contribute to increased risk in some individual patients can-
not be excluded, potentially impacting management deci-
sions on a case-by-case basis.
In patients with HCM who have chest pain and who un-
dergo coronary angiography, the finding of a myocardial
bridge raises the question of whether myocardial ischemia
associated with the bridge is the cause of symptoms. There
are no data assessing stress MPI in patients with HCM with
myocardial bridges; however, reports of patients with myo-
cardial bridges who do not have HCM suggest that stress
perfusion abnormalities may be commonly detected in the
vascular territory distal to the bridge.205 Although it has
been suggested that systolic compression of a bridged cor-
onary artery may not be responsible for ischemia because
most coronary blood flow takes place in diastole, angio-
graphic studies have demonstrated arterial compression in
diastole as well.206,207
If chest pain symptoms in a patient with HCM are sus-
pected to be related to abnormal coronary blood flow (as
a result of bridging), beta blockers may be effective in con-
trolling the symptoms. Intravenous beta blockade in pa-
tients with myocardial bridges and non-HCM disease has
been shown to have favorable effects on coronary dimen-
sions and myocardial blood flow and diminished ischemiagery c December 2011
Gersh et al Clinical Guidelineinduced by pacing tachycardia.207 If medical therapy is
ineffective, consideration can be given to surgery with
supra-arterial myotomy (‘‘unroofing’’),206,208 which may be
technically challengingdependingon thedepthof the tunneled
segment. CTA can define the course and depth of a bridged
segment and may be useful in planning surgical strategy.209
In patients with HCMwho are undergoing surgical myec-
tomy and in whom preoperative angiography has demon-
strated a myocardial bridge, there are no data to guide the
decision on whether to ‘‘unroof’’ the bridged segment dur-
ing the surgical myectomy. In patients with chest pain in
whom perfusion imaging demonstrates blunted flow reserve
distal to the myocardial bridge, supra-arterial myotomy has
been suggested to reduce anginal symptoms.
5.4.1. Choice of Imaging Modality
5.4.1.1. Invasive Coronary Arteriography
Invasive coronary arteriography is the gold standard for
defining the presence, extent, severity, and location of epi-
cardial coronary stenoses. Performance of invasive coro-
nary arteriography is indicated in patients with HCM
when knowledge of these features will importantly influ-
ence management strategies as discussed above. Invasive
coronary arteriography should be a routine accompaniment
to an invasive catheterization performed in a patient with
HCM for assessment of hemodynamic status and in such
cases should generally be performed after documentation
of hemodynamics so as not to influence important measure-
ments such as the magnitude of the LVOT gradient. When
catheterization is performed, invasive coronary arteriogra-
phy should be undertaken before alcohol septal ablation
in order to define the anatomy of the septal perforators in
detail and exclude obstructive coronary stenoses. Further-
more, if alcohol septal ablation is being considered, the de-
cision may be influenced by the location and extent of
coronary disease as defined by coronary arteriography.
5.4.1.2. Noninvasive CTA
Although there are no published data specifically assess-
ing the performance characteristics of CTA for document-
ing the presence or absence of epicardial CAD in HCM,
there is no reason to believe that performance of the test
should differ in patients with HCM compared with those
with suspected or known CAD. Many studies have reported
very good capability of contemporary CTA technology to
distinguish the presence from absence of a>50% epicardial
stenosis.210 A high negative predictive value to exclude
CAD is particularly consistent in the literature. In this re-
gard, for patients with HCM with chest discomfort, CTA
would be a reasonable strategy to assess for possible con-
comitant CAD. Anatomical demonstration of an epicardial
stenosis does not necessarily indicate that the symptoms of
chest discomfort are attributable to ischemia but areThe Journal of Thoracic and Carsuggestive and outlines a potential management strategy,
as well as indicates the need for specific preventive
strategies.
5.4.1.3. Single Photon Emission Computed Tomography
Myocardial Perfusion Imaging
Stress SPECTMPI in patients with HCMwill often dem-
onstrate reversible or fixed perfusion defects consistent with
ischemia or infarction, respectively, even in the absence of
epicardial CAD.211,212 In 1 study, approximately 50% of
young patients with HCM (unlikely to have CAD attribut-
able to age) had reversible perfusion defects on exercise
stress SPECTMPI that were prevented when exercise imag-
ing was repeated on verapamil.213 Several lines of evidence
support that these defects, even in the absence of symptoms,
represent true flow abnormalities and possibly ‘‘silent’’ is-
chemia. Studies of autopsy specimens or myectomy speci-
mens in patients with HCM have shown that patients with
HCM may have structural abnormalities of the myocardial
microvasculature.87 During pacing-induced tachycardia,
patients with HCM with reversible SPECT MPI defects
demonstrate production of lactate consistent with ische-
mia,214 and following relief of outflow tract obstruction
with myectomy, patients with HCM with reversible defects
often have normal perfusion.215
Fixed defects may also be seen with SPECT MPI, a find-
ing consistent with infarction. These patients will often
have the ‘‘end-stage’’ clinical phenotype with reduced
EF211 and likely correspond to patients who demonstrate
LGE in CMR studies.39
The concept that true abnormalities of perfusion at the
tissue level may be demonstrated by SPECTMPI in patients
with HCM in the absence of epicardial CAD, however, does
make the interpretation of SPECTMPI to detect CAD chal-
lenging. Moreover, myocardial ischemia in patients with
HCM, in the absence of epicardial coronary artery stenosis,
may be attributable to intramural small-vessel abnormali-
ties or massive hypertrophy.216 Given the above discussion,
the positive predictive value of an abnormal SPECT MPI
study for epicardial obstructive CAD in a patient with
HCM with chest discomfort will be relatively low, but the
negative predictive value will be high. The demonstration
of a reversible defect, even in the absence of CAD, does
suggest that the symptoms of chest discomfort may be
caused by ischemia, although not necessarily related to
the presence of obstructive CAD. Although the true perfor-
mance characteristics of SPECT MPI for detection of CAD
have not been rigorously studied in patients with HCM, it
would be expected that the negative predictive value should
be high.
In considering any imaging procedure that involves expo-
sure to radiation such as SPECT or PET imaging (Section
5.4.1.4), CTA (5.4.1.2) or invasive procedures, contempo-
rary recommendations suggest that the potential risks ofdiovascular Surgery c Volume 142, Number 6 e169
Clinical Guideline Gersh et alradiation exposure be taken into account and that the bene-
fits of the information gained sufficiently balance those
risks.217 This concept may be particularly important in pa-
tients with HCM, who in general will be younger compared
with other subgroups of patients being evaluated for heart
disease.
Interpretation of SPECT perfusion imaging studies in pa-
tients with HCM should be mindful that areas with substan-
tial wall thickening may appear inordinately ‘‘hot,’’ making
other areas without hypertrophy appear to have a relatively
mild reduction in tracer activity. Quantitative analysis pro-
grams may falsely interpret this as a perfusion defect. More-
over, gated SPECT analysis of EF with use of contouring
programs may underestimate EF, because the assumptions
driving the contouring algorithms searching for the endo-
cardial borders may not be reliable in some patients with
HCM because of the relative brightness of the hypertro-
phied wall.
5.4.1.4. Positron Emission Tomography
PET imaging has been used in patients with HCM to
study myocardial blood flow as well as myocardial metab-
olism. In patients with HCM with normal coronary arteries,
myocardial perfusion PET studies have shown that although
resting myocardial blood flow may be similar to that of nor-
mal control subjects, the augmentation of blood flow with
vasodilation, for example, dipyridamole, may be signifi-
cantly blunted.218-221 In addition, such abnormal myocar-
dial blood flow reserve was shown to be more pronounced
in the subendocardial regions, consistent with so-called
‘‘apparent’’ transient ischemic cavity dilatation.212,218,219
In 1 study using techniques to quantify myocardial blood
flow reserve with PET perfusion tracers, patients with
HCM who had blunted flow reserve in response to hyper-
emic stress had more unfavorable event-free survival com-
pared with patients with preserved hyperemic flow
reserve.220 A follow-up study suggested that 1 mechanism
for the unfavorable outcomes associated with the flow re-
serve abnormalities included progression to a remodeled,
end-stage phenotype.221 These findings are consistent
with the concept that repetitive episodes of myocardial is-
chemia may influence long-term outcome of patients with
HCM. However, the quantitative PET techniques used in
these studies are not part of routine clinical practice, and
the management implications of identifying abnormalities
in flow reserve are unresolved.
5.4.1.5. Stress Echocardiography
There are no published studies addressing the perfor-
mance characteristics of stress echocardiography to detect
or exclude CAD in patients with HCM. Although perfor-
mance of this modality has been well studied in patients
who do not have HCM and criteria about appropriate use
of the test exist,222 aspects of the HCM phenotype woulde170 The Journal of Thoracic and Cardiovascular Surin theory undermine performance. Patients with HCM
have heterogeneous wall-thickness patterns, and wall mo-
tion at rest may appear abnormal in regions of hypertro-
phied myocardium. A wall-motion response to stress
therefore would be complex to interpret and may be partic-
ularly so in the presence of the enhanced loading that occurs
in the setting of outflow tract obstruction, which may be
seen in up to 75% of patients during exercise. For these rea-
sons, stress echocardiography to detect or rule out CAD
may be unreliable in HCM but may be useful to document
the presence or magnitude of outflow tract obstruction gen-
erated by exercise8 (Section 4.1).
6. MANAGEMENT OF HCM
Treatment of patients with HCM requires a thorough un-
derstanding of the complex, diverse pathophysiology and
natural history and must be individualized to the patient.
The general approach of the writing committee is outlined
in Figure 3.
6.1. Asymptomatic Patients—Recommendations
Class I
1. For patients with HCM, it is recommended that comorbidities that
may contribute to cardiovascular disease (eg, hypertension, diabe-
tes, hyperlipidemia, obesity) be treated in compliance with relevant
existing guidelines.223 (Level of Evidence: C)
Class IIa
1. Low-intensity aerobic exercise is reasonable as part of a healthy life-
style for patients with HCM.10,224 (Level of Evidence: C)
Class IIb
1. The usefulness of beta blockade and calcium channel blockers to al-
ter clinical outcome is not well established for the management of
asymptomatic patients with HCM with or without obstruction.10
(Level of Evidence: C)
Class III: Harm
1. Septal reduction therapy should not be performed for asymptom-
atic adult and pediatric patients with HCM with normal effort tol-
erance regardless of the severity of obstruction.9,10 (Level of
Evidence: C)
2. In patients with HCM with resting or provocable outflow tract ob-
struction, regardless of symptom status, pure vasodilators and high-
dose diuretics are potentially harmful.3,9 (Level of Evidence: C)
A large proportion of patients presenting with HCM are
asymptomatic, and most will achieve a normal life expec-
tancy.48,131,225 It is essential to educate these patients and
their families about the disease process, including screening
of first-degree relatives and avoiding particularly strenuous
activity or competitive athletics.134 Risk stratification for
SCD should also be performed in all patients, irrespective
of whether symptoms are present.9,10gery c December 2011
FIGURE 3. Treatment algorithm. ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DM, diabetes mellitus; EF, ejection fraction;
GL, guidelines; HCM, hypertrophic cardiomyopathy; HTN, hypertension; LV, left ventricular.
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Clinical Guideline Gersh et alBecause concomitant CAD has a significant impact on
survival in patients with HCM,199 it is recommended that
other risk factors that may contribute to atherosclerotic car-
diovascular disease be treated aggressively in concordance
with existing guidelines (Figure 3).10,223 This includes ag-
gressive modification of risk factors such as hypertension,
diabetes, obesity, and hyperlipidemia.223 A low-intensity
aerobic exercise program is also reasonable to achieve car-
diovascular fitness.224
Hydration and avoidance of environmental situations
where vasodilatation may occur are important in the asymp-
tomatic patient with resting or provocable LVOT obstruc-
tion. High-dose diuretics and vasodilators (for treatment
of other diseases such as hypertension) should be avoided,
because these may exacerbate the degree of obstruction.3,9
However, the lack of symptoms attributable to HCM should
not detract from the use of negative inotropic agents such as
beta blockers or calcium channel blockers as treatment for
relevant comorbidities such as hypertension.10 Although
data support the use of verapamil to relieve symptoms in
HCM, other calcium antagonists such as diltiazem, even
though widely used, have not been studied systematically.
Preliminary data in the animal model suggest that inhib-
itors of the renin-angiotensin pathway or statins or the
calcium channel inhibitor diltiazem226 may prevent pro-
gression of hypertrophy in animal models of HCM.227,228
However, there is no completed RCT to indicate that these
drugs are effective in reducing hypertrophy in humans with
HCM. Thus, these drugs should not be given with the intent
of altering HCM-related clinical outcome but only for the
control of heart failure–related symptoms. Finally, the indi-
cation for septal reduction therapy is to improve symptoms
that are not relieved by medical therapy and that impair the
patient’s quality of life, usually consistent with NYHA
functional classes III or IV.9,10 Thus, septal reduction ther-
apy with either septal myectomy or alcohol septal ablation
should not be performed in the asymptomatic patient, re-
gardless of the severity of obstruction.9,10
6.2. Symptomatic Patients
6.2.1. Pharmacologic Management—Recommendations
Class I
1. Beta-blocking drugs are recommended for the treatment of symp-
toms (angina or dyspnea) in adult patients with obstructive or non-
obstructive HCM but should be used with caution in patients with
sinus bradycardia or severe conduction disease.3,9,10,134,137,229-236
(Level of Evidence: B)
2. If low doses of beta-blocking drugs are ineffective for controlling
symptoms (angina or dyspnea) in patients with HCM, it is useful
to titrate the dose to a resting heart rate of less than 60 to 65 bpm
(up to generally accepted and recommended maximum doses of
these drugs).3,10,137,229-236 (Level of Evidence: B)
3. Verapamil therapy (starting in low doses and titrating up to 480
mg/d) is recommended for the treatment of symptoms (angina ore172 The Journal of Thoracic and Cardiovascular Surdyspnea) in patients with obstructive or nonobstructive HCM
who do not respond to beta-blocking drugs or who have side effects
or contraindications to beta-blocking drugs. However, verapamil
should be used with caution in patients with high gradients, ad-
vanced heart failure, or sinus bradycardia.10,134,137,237-241 (Level of
Evidence: B)
4. Intravenous phenylephrine (or another pure vasoconstricting
agent) is recommended for the treatment of acute hypotension in
patients with obstructive HCM who do not respond to fluid admin-
istration.137,242-244 (Level of Evidence: B)
Class IIa
1. It is reasonable to combine disopyramide with a beta-blocking drug
or verapamil in the treatment of symptoms (angina or dyspnea) in
patients with obstructiveHCMwho do not respond to beta-blocking
drugs or verapamil alone.10,134,137,245-248 (Level of Evidence: B)
2. It is reasonable to add oral diuretics in patients with nonobstructive
HCM when dyspnea persists despite the use of beta blockers or ve-
rapamil or their combination.67,134 (Level of Evidence: C)
Class IIb
1. Beta-blocking drugs might be useful in the treatment of symptoms
(angina or dyspnea) in children or adolescents with HCM, but pa-
tients treated with these drugs should be monitored for side effects,
including depression, fatigue, or impaired scholastic performance.
(Level of Evidence: C)
2. It may be reasonable to add oral diuretics with caution to patients
with obstructive HCM when congestive symptoms persist despite
the use of beta blockers or verapamil or their combination.10,134,137
(Level of Evidence: C)
3. The usefulness of angiotensin-converting enzyme inhibitors or an-
giotensin receptor blockers in the treatment of symptoms (angina
or dyspnea) in patients with HCM with preserved systolic function
is not well established, and these drugs should be used cautiously (if
at all) in patients with resting or provocable LVOT obstruction.
(Level of Evidence: C)
4. In patients withHCMwho do not tolerate verapamil or in whom ve-
rapamil is contraindicated, diltiazem may be considered. (Level of
Evidence: C)Class III: Harm
1. Nifedipine or other dihydropyridine calcium channel-blocking
drugs are potentially harmful for treatment of symptoms (angina
or dyspnea) in patients with HCM who have resting or provocable
LVOT obstruction. (Level of Evidence: C)
2. Verapamil is potentially harmful in patients with obstructive HCM
in the setting of systemic hypotension or severe dyspnea at rest.
(Level of Evidence: C)
3. Digitalis is potentially harmful in the treatment of dyspnea in pa-
tients with HCMand in the absence of AF.3,10,137,249-251 (Level of Ev-
idence: B)
4. The use of disopyramide alone without beta blockers or verapa-
mil is potentially harmful in the treatment of symptoms (angina
or dyspnea) in patients with HCM with AF because disopyramide
may enhance atrioventricular conduction and increase the ven-
tricular rate during episodes of AF.10,66,134,252-257 (Level of
Evidence: B)
5. Dopamine, dobutamine, norepinephrine, and other intravenous
positive inotropic drugs are potentially harmful for the
treatment of acute hypotension in patients with obstructive
HCM.3,82,242-244,258-260 (Level of Evidence: B)gery c December 2011
*Experienced operators are defined as an individual operator with a cumulative case
volume of at least 20 procedures or an individual operator who is working in a ded-
icated HCM program with a cumulative total of at least 50 procedures (Section
6.2.2.3).
yEligible patients are defined by all of the following:
a. Clinical: Severe dyspnea or chest pain (usually NYHA functional classes III or
IV) or occasionally other exertional symptoms (such as syncope or near syn-
cope) that interfere with everyday activity or quality of life despite optimal med-
ical therapy.
b. Hemodynamic: Dynamic LVOT gradient at rest or with physiologic provocation
50 mm Hg associated with septal hypertrophy and SAM of the mitral valve.
c. Anatomic: Targeted anterior septal thickness sufficient to perform the procedure
safely and effectively in the judgment of the individual operator.
Gersh et al Clinical GuidelineThe major goal of pharmacologic therapy in symptom-
atic patients with HCM is to alleviate symptoms of exer-
tional dyspnea, palpitations, and chest discomfort, which
may reflect pathophysiologic mechanisms such as LVOT
obstruction, reduced supply of myocardial oxygen, mitral
regurgitation, and impaired LV diastolic relaxation and
compliance.9,10,134
Beta blockers are the mainstay of pharmacologic therapy
and the first-line agents because of their negative inotropic
effects261 and their ability to attenuate adrenergic-induced
tachycardia (Figure 3). These effects improve myocardial
oxygen supply-demand relationships and hence reduce
myocardial ischemia. The reduction in heart rate also pro-
longs the diastolic filling period, which may allow for
more efficient inactivation of myocardial contractile pro-
teins, thereby improving diastolic filling.262,263
In those patients unable to tolerate beta blockers or those
with symptoms unresponsive to beta blockers, calcium
channel blockers may provide effective symptomatic relief.
Verapamil has been the most intensively studied such agent
(Figure 3).239,264 Possible mechanisms for symptomatic im-
provement include negative inotropic and rate-lowering ef-
fects similar to those of beta blockers. However, the effect
of verapamil on diastolic dysfunction is controver-
sial.84,265-268 Whether improvement in indices of diastolic
performance is a direct effect of verapamil or the result of
reduction in ischemia is uncertain.213 Diltiazem has also
been shown to improve measures of diastolic perfor-
mance269 and to prevent or diminish myocardial ische-
mia.270 Both verapamil and diltiazem should be used
cautiously in patients with severe outflow tract obstruction,
elevated pulmonary artery wedge pressure, and low sys-
temic blood pressure, because a decrease in blood pressure
with treatment may trigger an increase in outflow obstruc-
tion and precipitate pulmonary edema. Administration of
beta-blocking drugs with either verapamil or diltiazem
should also be performed with caution because of the poten-
tial for high-grade atrioventricular block. In addition, be-
cause of the bradycardic effects when both classes of
agents are used concomitantly, the addition of verapamil
or diltiazem to a beta blocker may prevent titration of the
beta blocker to optimal dosage. Dihydropyridine class cal-
cium channel blockers (eg, nifedipine) should not be used in
patients with obstructive physiology because their vasodila-
tory effects may aggravate outflow obstruction.
In patients with obstructive HCM who remain symptom-
atic despite the use of beta blockers and calcium channel
blockers, alone or in combination, disopyramide may be ef-
fective in ameliorating symptoms in many patients
(Figure 3).157,271 Anticholinergic side effects may occur
and can be managed if necessary by dose reduction. Symp-
tomatic benefit with disopyramide appears to represent
a pure negative inotropic effect. The initiation of disopyra-
mide should be performed in-hospital with cardiacThe Journal of Thoracic and Carmonitoring for potential arrhythmias and lengthening of
the QT. Diuretics may be effective for symptomatic relief
in patients with pulmonary congestion but should be used
judiciously in those with outflow tract obstruction.
6.2.2. Invasive Therapies—Recommendations
Class I
1. Septal reduction therapy should be performed only by experienced
operators* in the context of a comprehensive HCM clinical pro-
gram and only for the treatment of eligible patients with severe
drug-refractory symptoms and LVOT obstruction.y272 (Level of
Evidence: C)
Class IIa
1. Consultation with centers experienced in performing both surgical
septal myectomy and alcohol septal ablation is reasonable when dis-
cussing treatment options for eligible patients with HCM with se-
vere drug-refractory symptoms and LVOT obstruction. (Level of
Evidence: C)
2. Surgical septal myectomy, when performed in experienced centers,
can be beneficial and is the first consideration for the majority of el-
igible patients with HCM with severe drug-refractory symptoms
and LVOT obstruction.61,62,155,273-275 (Level of Evidence: B)
3. Surgical septal myectomy, when performed at experienced centers,
can be beneficial in symptomatic children with HCM and severe
resting obstruction (>50 mm Hg) for whom standard medical ther-
apy has failed.276 (Level of Evidence: C)
4. When surgery is contraindicated or the risk is considered unaccept-
able because of serious comorbidities or advanced age, alcohol sep-
tal ablation, when performed in experienced centers, can be
beneficial in eligible adult patients with HCM with LVOT obstruc-
tion and severe drug-refractory symptoms (usually NYHA func-
tional classes III or IV).62,153,277–281 (Level of Evidence: B)
Class IIb
1. Alcohol septal ablation, when performed in experienced centers,
may be considered as an alternative to surgical myectomy for eligi-
ble adult patients with HCMwith severe drug-refractory symptoms
and LVOTobstruction when, after a balanced and thorough discus-
sion, the patient expresses a preference for septal abla-
tion.153,273,278,280,281 (Level of Evidence: B)
2. The effectiveness of alcohol septal ablation is uncertain in patients
with HCM with marked (ie, >30 mm) septal hypertrophy, and
therefore the procedure is generally discouraged in such patients.
(Level of Evidence: C)diovascular Surgery c Volume 142, Number 6 e173
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1. Septal reduction therapy should not be done for adult patients with
HCM who are asymptomatic with normal exercise tolerance or
whose symptoms are controlled or minimized on optimal medical
therapy. (Level of Evidence: C)
2. Septal reduction therapy should not be done unless performed as
part of a program dedicated to the longitudinal and multidisciplin-
ary care of patients with HCM. (Level of Evidence: C)
3. Mitral valve replacement for relief of LVOTobstruction should not
be performed in patients with HCM in whom septal reduction ther-
apy is an option. (Level of Evidence: C)
4. Alcohol septal ablation should not be done in patients with HCM
with concomitant disease that independently warrants surgical cor-
rection (eg, coronary artery bypass grafting for CAD, mitral valve
repair for ruptured chordae) in whom surgical myectomy can be
performed as part of the operation. (Level of Evidence: C)
5. Alcohol septal ablation should not be done in patients with HCM
who are less than 21 years of age and is discouraged in adults less
than 40 years of age if myectomy is a viable option. (Level of
Evidence: C)
See Online Data Supplement 2 for additional data re-
garding invasive therapies.
Although the writing committee recognizes that surgical
myectomy and ablation are methodologically very different
approaches and interventions, in this section they are dis-
cussed together because they are the 2 generally accepted
methods for relief of symptoms in patients with LVOT ob-
struction. Most patients with HCM lead active lifestyles
with minimal or no symptoms, but some patients incur sig-
nificant symptoms that interfere with everyday activity or
quality of life.48 For symptoms that are attributable to
LVOT obstruction, invasive therapies can be used to im-
prove quality of life (Figure 3). Surgical approaches have
been used for 5 decades72,144 so that relief of outflow tract
obstruction and symptoms can be achieved with minimal
perioperative morbidity or mortality in experienced cen-
ters.61,155 However, some patients are not optimal surgical
candidates (eg, because of comorbidities or advanced age)
or have such a strong desire to avoid surgery that alternative
therapeutic interventions have been implemented. Alcohol
septal ablation, which has been in use for the past 17 years,
has become the leading strategy in these circumstances.282
This procedure causes a regional infarction of the basal sep-
tum, thereby initially decreasing contractility and eventu-
ally causing thinning (because of scarring) of the basal
septum and consequent widening of the outflow tract.
Dual-chamber pacing has also been used and studied for
the relief of outflow tract obstruction. The proposed mech-
anism relates to a change in the activation sequence of the
septum and possibly long-term remodeling. RCTs sug-
gested a modest benefit of pacing therapy, primarily in those
>65 years of age.283,284 In the current era, application of
dual-chamber pacing for the relief of symptoms attributable
to outflow tract obstruction is primarily used in patients
with significant comorbidities for whom both surgicale174 The Journal of Thoracic and Cardiovascular Surseptal myectomy and alcohol septal ablation are considered
to have unacceptable risk or in patients who already have an
implanted dual-chamber pacing device (often implanted for
nonhemodynamic indications).
6.2.2.1. Selection of Patients
It is well recognized that the appropriate selection of pa-
tients for individual procedures is an important predictor of
outcome. Because the majority of patients with HCM can
achieve control of their symptoms with optimal pharmaco-
logic therapy, and in light of the complications inherent
with invasive therapies, a core set of clinical, anatomic,
and hemodynamic criteria are required before patients are
considered candidates for invasive therapies. Specifically,
patients must have symptoms attributable to LVOTobstruc-
tion that are refractory to optimal pharmacologic therapy.
Similarly, it must be demonstrated that the obstruction is
caused by apposition of the mitral valve with the hypertro-
phied septum (and not attributable to systolic cavity obliter-
ation).72,144 It has been generally accepted that maximal
instantaneous gradients of at least 50 mm Hg at rest or
with physiologic provocation are necessary to produce
symptoms amenable to invasive therapies.10
Given the duration of experience, documented long-term
results, and safety data, surgical septal myectomy is consid-
ered the preferred treatment for most patients who meet
these criteria (Figure 3). Considerations that would favor
surgical intervention include younger age, greater septal
thickness, and concomitant cardiac disease independently
requiring surgical correction (eg, intrinsic mitral valve dis-
ease or coronary artery bypass grafting). Additionally, spe-
cific abnormalities of the mitral valve and its support
apparatus can contribute significantly to the generation of
outflow tract obstruction, suggesting the potential value of
additional surgical approaches (eg, plication, valvuloplasty,
and papillary muscle relocation) and making myectomy
more appropriate than alcohol septal ablation in some pa-
tients.16,80,285-290 Among patients who meet the core selec-
tion criteria, factors that influence a decision to proceed
with alcohol septal ablation include older or advanced
age, significant comorbidity that selectively increases surgi-
cal risk, (eg, significant concerns about lung or airway man-
agement) and the patient’s strong desire to avoid open-heart
surgery after a thorough discussion of both options.
6.2.2.2. Results of Invasive Therapy for the Relief of LVOT
Obstruction
More detailed discussions specific to each type of proce-
dure follow in subsequent sections of this document. Over-
all, reports suggest that technical success, variably defined,
is achieved in 90% to 95% of patients who undergo surgi-
cal myectomy,291 less in septal ablation, and only in the
minority of patients studied in trials of pacemaker ther-
apy.292-295 Patients undergoing septal ablation may havegery c December 2011
Gersh et al Clinical Guidelinehemodynamic and symptomatic improvement comparable
to septal myectomy if the area of the SAM-septal contact
can be accessed by the first septal perforator and ablated.
However, compared with septal myectomy in which the hy-
pertrophied muscle is directly visualized and resected, suc-
cessful septal ablation is dependent on the variable septal
artery anatomy, which may not supply the targeted area of
the septum in up to 20% to 25% of patients.62,296
In a nonrandomized retrospective evaluation of patients
with HCM<65 years of age, survival free from recurrent
symptoms favored myectomy over ablation (89% versus
71%, P ¼ 0.01).62 Procedural success is associated with
very low mortality (<1% for myectomy,61,155,297 ranging
from 0% to 4% for ablation),298-300 and low nonfatal com-
plication rates (2% to 3% in experienced centers). The ex-
ception is high-grade atrioventricular block requiring
permanent pacemakers following septal ablation (in 10%
to 20% of patients), an inherent aspect of the septal infarc-
tion.301-303 The data from trials of dual-chamber pacing
suggest that there was a significant placebo effect and in-
consistent symptomatic benefit.283,284,294
6.2.2.3. Operator Experience
Operator and institutional experience, including procedural
volume, is a key determinant of successful outcomes and
lower complication rates for any procedure. For HCM, a dis-
ease of substantial heterogeneity that is relatively uncommon
in general cardiology practice, this is an important issue. As
with the recommendationsmade in the ‘‘2008FocusedUpdate
Incorporated Into theACCF/AHAGuidelines for theManage-
mentofPatientsWithValvularHeartDisease’’ about expected
outcomes for surgeons offeringmitral valve repair,304 it would
be prudent and appropriate for individual centers, surgeons,
and interventional cardiologists to demonstrate sufficient
success and safety to justify ongoing use of these procedures.
Although it is difficult to define a precise case volume or
cumulative experience required to perform these procedures,
at least 1 study suggests that the learning curve relative to in-
vasive therapy inHCMmayrequire theperformanceof at least
40 procedures.272 As a consensus opinion, the writing
committee recommends an operator volume of at least 20
procedures or that the operator work within the context of
an HCM program with a cumulative procedural volume of
at least 50 procedures. In addition, given the data available
from experienced centers, operators and institutions should
aim to achievemortality rates of<1% andmajor complication
ratesof<3%,with documented success in bothhemodynamic
and symptombenefit for their patients. This is best achieved in
the context of a systematic program dedicated to the multidis-
ciplinary and longitudinal care of patients with HCM.
6.2.2.4. Surgical Therapy
Transaortic septal myectomy is currently considered the
most appropriate treatment for the majority of patients withThe Journal of Thoracic and Carobstructive HCM and severe symptoms unresponsive to
medical therapy (Figure 3).276,291,305-313 Surgical results,
although vastly improved in recent years, are nevertheless
limited to relatively few centers with extensive experience
and particular interest in the management of HCM.288,314
Both the traditional myectomy (Morrow procedure) with
about a 3-cm long resection309 or extended myectomy (a re-
section of about 7 cm) are currently used.288,314
The transaortic approach remains the primary method
of exposure. Virtual abolition of the LV outflow gradient
and mitral regurgitation is usually accomplished by mus-
cular resection resulting in physical enlargement of the
outflow tract and by interruption of the mitral valve
SAM, which is usually responsible for the outflow gradi-
ent.315 Septal myectomy in the current era is commonly
referred to as an ‘‘extended myectomy.’’ This refers to
the fact that the muscular resection becomes progres-
sively wider as the resection proceeds into the ventricle
(ie, toward the apex), effectively making the trough wider
at the mid-ventricular level. As a result, the myectomy re-
section is opposite the lateral portion of the anterior leaf-
let (to avoid conduction tissue), the chordae, and both
papillary muscles. In addition, muscular resection is
also performed along the left lateral free wall (also part
of the LVOT), resulting in a much more extensive myec-
tomy than that originally described by Morrow et al about
50 years ago.309
The transaortic approach remains the primary method
of exposure. Virtual abolition of the LV outflow gradient
and mitral regurgitation is usually accomplished by mus-
cular resection resulting in physical enlargement of the
outflow tract and by interruption of the mitral valve
SAM, which is usually responsible for the outflow gradi-
ent.315 In selected circumstances, some surgeons have
also used concomitant mitral valve repair, particularly
when the anterior leaflet is elongated. This valve repair
maneuver usually involves shortening the height of the
anterior leaflet. However, residual mitral valve regurgita-
tion after adequate septal myectomy is almost always
caused by intrinsic mitral valve abnormalities such as rup-
tured chordae, myxomatous degeneration with prolapse,
or annular dilatation, and can be corrected by direct valve
repair. Finally, enlarged or malpositioned papillary mus-
cles can also contribute to residual obstruction. This can
be effectively treated by shaving the hypertrophied papil-
lary muscles, incising papillary muscles off the ventricu-
lar free wall, and in selected circumstances repositioning
one papillary muscle by suture approximation to the adja-
cent papillary muscle.
The surgical specimen obtained at the time of myec-
tomy should be submitted for pathologic examination,
not only to confirm the histopathology of HCM, but
also for special stains to rule out storage diseases that
can mimic HCM.31diovascular Surgery c Volume 142, Number 6 e175
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score that the subjective assessment of operative risk by cli-
nicians frequently results in an overestimate of risk,
resulting in the denial of proven therapies for eligible pa-
tients in favor of less effective or less proven options.316
In patients perceived to be at prohibitively high risk because
of major comorbidities, including age, the use of objective
risk tools in the context of individual institutional experi-
ence could lead to a reassessment of operative risk that is
lower than initially thought.
6.2.2.4.2. Outcomes
Early Results.Based on the experience and data assembled
from multiple centers worldwide over the last 4 de-
cades,276,291,305,307,308,310,311 septal myectomy is estab-
lished as the most effective and proven approach for
reversing the consequences of heart failure by providing
amelioration of obstruction (and relief of mitral regurgita-
tion) at rest, with restoration of functional capacity and ac-
ceptable quality of life at any age, exceeding that achievable
with long-term administration of cardioactive drugs.10,175
These salutary benefits have been demonstrated subjec-
tively by patient history and objectively by increased tread-
mill time, maximum workload, peak oxygen consumption,
and improvedmyocardial oxygen demand, metabolism, and
coronary flow.10,273,294
LV outflow gradient reduction with myectomy results
from basal septal thinning with resultant enlargement of
the LVOT area (and redirection of forward flow with loss
of the drag and Venturi effects on the mitral valve)317 and
consequently abolition of SAM and mitral-septal con-
tact.314,318,319 Mitral regurgitation is also usually eliminated
without the need for additional mitral valve surgery.148With
myectomy, LA size (and possibly long-term risk for AF) is
reduced155 and LV pressures (and wall stress) are normal-
ized.10,61,148,317,320 Thus, obstructive HCM is a surgically
and mechanically reversible form of heart failure. In expe-
rienced centers, operative risk is now particularly low, in the
range of<1%.175
Late Results. Relief of outflow obstruction by septal
myectomy may also extend the longevity of patients
with HCM.61 Although RCTs involving myectomy sur-
gery have not been performed, in a nonrandomized study,
myectomy resulted in excellent long-term survival similar
to that in the general population. After septal myectomy,
long-term actuarial survival was 99%, 98%, and 95% at
1, 5, and 10 years, respectively (when considering HCM-
related mortality). This survival rate did not differ from
that expected in a matched general US population and
was superior to that achieved by patients with obstructed
HCM who did not undergo surgical myectomy.61e176 The Journal of Thoracic and Cardiovascular SurSimilarly, the rate of SCD or appropriate ICD discharge
after myectomy is very low (<0.9%).61,321,322 Nonethe-
less, surgical myectomy does not eliminate the need to as-
sess each patient’s risk for SCD and to consider
placement of an ICD in those with a significant risk
burden.
6.2.2.4.3. Complications. Complications following myec-
tomy are rare when performed in experienced centers.315
The risk of complete heart block is approximately 2%
with myectomy (higher in patients with preexisting right
bundle-branch block), but in myectomy patients who have
had previous alcohol septal ablation, risk is much higher
(50% to 85%).323 Iatrogenic ventricular septal defect oc-
curs in<1% of patients. Finally, the risk of aortic valve
or mitral valve injury is also low (<1%), particularly
when myectomy is performed by an experienced operator.
6.2.2.4.4. Mitral Valve Abnormalities and Other Anatomic
Issues. Abnormalities of the mitral valve and subvalvar
apparatus (including anomalous direct anterolateral papil-
lary muscle insertion into anterior mitral leaflet and elon-
gated mitral leaflets)80,324 can be identified preoperatively
with TTE or intraoperative TEE and can be corrected with
modified mitral valve repair or extended myectomy tech-
niques without the need for mitral valve replacement. In-
deed, the excellent early and late outcomes of extended
myectomy for treatment of obstructive HCM have made
mitral valve replacement exceedingly rare.315 Associated
degenerative mitral valve disease (ie, prolapse, ruptured
chordae) can be treated by concomitant mitral valve re-
pair at the time of myectomy. Mitral valve repair tech-
niques may need to be modified in HCM to avoid
subsequent development of SAM.325
Mitral valve replacement in patients with obstruction has
been performed rarely when septal reduction therapy was
judged unsafe or likely to be ineffective. When the basal
septum is only mildly hypertrophied (<16 mm), the risk
for either iatrogenic ventricular septal defect from excessive
muscular resection or residual postoperative outflow ob-
struction from inadequate resection increases. Mitral valve
replacement may be an option in rare patients.326,327
6.2.2.5. Alcohol Septal Ablation. First reported in 1995,282
alcohol septal ablation uses transcoronary administration
of absolute ethanol via a percutaneous approach to induce
a localized infarction of the basal septum at the point of con-
tact of the anterior mitral valve leaflet, thereby reducing
outflow tract gradient and associated mitral regurgitation
and simulating the results of surgical myectomy. Developed
as an alternative to surgical septal myectomy, the technique
is particularly useful when surgery is contraindicated and in
patients who are considered poor surgical candidates.279gery c December 2011
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formed successfully in a large number of patients.153
After measurement of resting or provoked outflow tract
gradients, a temporary pacemaker is placed in the right ven-
tricle because of the risk of procedural complete heart
block.328-330 With the use of standard angioplasty equip-
ment and anticoagulation, a guidewire and coronary angio-
plasty balloon are placed in the septal perforator that
appears to perfuse the target myocardium. Contrast
angiography of the septal perforator through the balloon
central lumen with simultaneous echocardiographic guid-
ance331,332 confirms delivery to only the target myocar-
dium. About 1 to 3 mL of alcohol is infused in controlled
fashion.151,333-335 Incorporation of myocardial contrast
echocardiography reduces the number of septal branches
into which ethanol is injected and may both improve the
success rate and lower cardiac biomarker release and the
need for pacing.331-333,336 It is important that the balloon
be inflated and that a contrast injection also show that there
is no extravasation of dye into the distal left anterior
descending coronary artery. Contrast enhancement of other
regions (papillary muscles, free wall) indicates collateral
circulation from the septal perforator artery, and alcohol
should not be infused. A decrease in resting and provocable
gradients usually occurs immediately after the procedure
(because of stunning), and remodeling can result in contin-
ued or variable gradient reduction over the first 3 months
after the procedure. Patients are monitored for arrhythmias
and conduction disturbances in the intensive care unit for 24
to 48 hours; implantation of a permanent pacemaker may be
necessary for complete or high-grade atrioventricular block
and through discharge at 3 to 4 days.
6.2.2.5.1. Selection of Patients. Alcohol septal ablation has
the potential for greater patient satisfaction because of the
absence of a surgical incision and general anesthesia, less
overall discomfort, and a much shorter recovery time. The
benefit of alcohol septal ablation in patients of advanced
age is similar to that in other patients.277,337 Because the
postoperative risks and complications of cardiac surgery
increase with age, ablation may offer a selective advantage
in older patients, in whom operative risk may be increased
because of comorbidities. Alcohol septal ablation is not
indicated in children.
On the other hand, longer-term follow-up data are avail-
able for septal myectomy than for septal ablation, a consid-
eration relevant to the selection of patients for either septal
reduction therapy. The likelihood of implantation of a per-
manent pacemaker is 4- to 5-fold higher after septal ablation
than after septal myectomy. Clinical and hemodynamic
benefit is achieved immediately after recovery from septal
myectomy but may be delayed for up to 3 months after sep-
tal ablation, although many patients achieve a notable
symptomatic benefit after the procedure. Furthermore,The Journal of Thoracic and Carpatients with massive septal thickness approaching or ex-
ceeding 30mmmay experience little or no benefit from sep-
tal ablation. The surgeon can tailor the myectomy under
direct visualization to address specific anatomic abnormal-
ities of the LVOTor mitral valve apparatus, whereas alcohol
septal ablation indirectly (and is restricted to) targets the
distribution of the septal perforator artery.
Septal myectomy is the preferred treatment option for
most severely symptomatic patients with obstructive HCM,
especially in younger, healthy adults, whereas septal ablation
is preferred in patients for whom surgery is contraindicated
or considered high risk (particularly the elderly) (Figure 3).
Data comparing alcohol septal ablation with septal myec-
tomy are inadequate to fully inform clinical decision making
in certain cases. For such patients, the principle of patient au-
tonomy dictates that it is appropriate for the informed patient
to choose between the 2 procedures.
6.2.2.5.2. Results. Necrosis of the basal ventricular
septum338 produces an immediate fall in gradient from de-
creased septal contraction in >90% of patients.156,300,
339-341 This effect is followed by LV remodeling over 6 to
12 months, a process that includes scar retraction and resul-
tant widening of the outflow tract, associated with further
reduction in gradient and degree of mitral regurgitation,
regression of hypertrophy, and improvement in diastolic
function.154,300,342-344 LA pressure is reduced, which may
promote a decreased incidence of AF and amelioration of
pulmonary hypertension.345 Two studies have demonstrated
that, as with septal myectomy, the benefit of septal ablation
in patients with provocable gradients is similar to that in pa-
tients with resting gradients.346,347 The beneficial results of
alcohol septal ablation have been reported to almost 5 years
after the procedure with improved functional and angina
classes, exercise capacity, and quality of life.153,300,348-351
However, hemodynamic and symptomatic success is depen-
dent on the ability to cannulate and ablate a septal perforator
artery that supplies the area of the SAM-septal contact.
Although RCTs comparing surgical myectomy with
alcohol septal ablation have not been conducted and are
highly unlikely in the future, meta-analyses have noted sim-
ilar hemodynamic and functional improvement over 3 to 5
years when examining the cumulative average of out-
comes.352-354What themeta-analyses do not report are a sub-
set of patients in whom alcohol septal ablation is unreliable
because of the inability to ablate the area of the SAM-
septal contact.355 Older patients, especially those considered
to be at high surgical risk, may bewell served by alcohol sep-
tal ablation, whereas younger patients may benefit most from
surgical myectomy.62,279 Despite age differences in treat-
ment allocation, with septal ablation patients on average
approximately 10 years older in clinical practice,352,353 the
4-year survival rate is similar for the 2 procedures.62,278
Most studies that have compared surgical myectomy anddiovascular Surgery c Volume 142, Number 6 e177
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experience in which treatment assignment was not
randomized.
6.2.2.5.3. Complications. In approximately half of patients
undergoing alcohol septal ablation, temporary complete
atrioventricular block occurs during the procedure.328-330
Persistent complete heart block prompting implantation of
a permanent pacemaker occurs in 10% to 20% of patients
based on the available data.36 Approximately 5% of pa-
tients have sustained ventricular tachyarrhythmias during
hospitalization. The in-hospital mortality rate is up to
2%.62,153,279,353 Because of the potential for creating a ven-
tricular septal defect, septal ablation should not be per-
formed if the target septal thickness is 15 mm.
Alcohol septal ablation is a therapeutic alternative to sur-
gical myectomy for selected patients and produces a trans-
mural infarction of ventricular septum occupying on
average 10% of the overall LV wall.53,296,356 There has
been concern that the potential ventricular arrhythmogenic-
ity of the scar created by septal ablation might augment risk
in the HCM population. Several studies have documented
the occurrence of sustained ventricular arrhyth-
mias332,349,357-363 and SCD following septal ablation322 in
about 3% to 10% of patients both with or without risk fac-
tors for SCD. In a single-center experience (n¼ 91), 21% of
patients experienced sudden or other cardiac death, aborted
SCD, and/or appropriate ICDdischarge resulting in an annu-
alized event rate of 4.4% per year after ablation.322 In a sec-
ond single-center experience (n ¼ 89), no mortality was
attributable to SCD in 5.02.3 years of follow-up. However,
in a selected subset of 42 patients with an ICD or permanent
pacemaker that enabled detection of device-stored electro-
grams, the annualized event rate (VT, ventricular fibrilla-
tion, and/or appropriate ICD discharge, including
periprocedural arrhythmias) was 4.9% per year.362 Data
from another center suggest appropriate ICD intervention
rates after ablation of 2.8% per year364; similarly, the mul-
ticenter HCM ICD registry (n ¼ 506) demonstrated that
the rate of appropriate ICD therapy among ablation patients
with primary prevention ICDs was 3 to 4 times more fre-
quent than in other patients in that registry (10.3% per
year compared with 2.6% per year).55 Patients with HCM
considered to carry sufficient risk to warrant ICD placement
have an annual incidence of appropriate interventions for
VT/ventricular fibrillation of 3% to 10%.55,360,364 It is un-
certain how common such events are attributable to the pro-
cedure or alternatively to the underlying disease, but the
incidence of sustained ventricular arrhythmias after myec-
tomy is extremely low (0.2% to 0.9% per year).61,321,322
Meta-analyses have indicated no difference between septal
ablation and myectomy in the medium-term incidence of
SCD or all-cause mortality.352,365 Although no definitive ev-
idence is available that the ablation scar as such increases (ore178 The Journal of Thoracic and Cardiovascular Surdoes not increase) long-term risk for SCD in absolute terms in
this patient population, resolution will require greatly ex-
tended follow-up studies in larger patient cohorts.53,357
6.2.2.6. Pacing—Recommendations
Class IIa
1. In patients with HCM who have had a dual-chamber device im-
planted for non-HCM indications, it is reasonable to consider a trial
of dual-chamber atrial-ventricular pacing (from the right ventricu-
lar apex) for the relief of symptoms attributable to LVOT obstruc-
tion.292,294,295,366 (Level of Evidence: B)
Class IIb
1. Permanent pacingmay be considered inmedically refractory symp-
tomatic patients with obstructive HCM who are suboptimal candi-
dates for septal reduction therapy.283,292,294,295,366 (Level of
Evidence: B)
Class III: No Benefit
1. 1. Permanent pacemaker implantation for the purpose of reducing
gradient should not be performed in patients with HCM who are
asymptomatic or whose symptoms are medically con-
trolled.283,284,367 (Level of Evidence: C)
2. Permanent pacemaker implantation should not be performed as
a first-line therapy to relieve symptoms in medically refractory
symptomatic patients with HCM and LVOT obstruction who are
candidates for septal reduction.283,284,367 (Level of Evidence: B)
See Online Data Supplement 3 for additional data re-
garding pacing.
Implantation of a dual-chamber pacemaker was proposed
as an alternative treatment for patients with severe symptom-
atic obstructive HCM.369-371 Pacing the right ventricular
apex with maintenance of atrioventricular synchrony results
in a decrease in the LVOT gradient and improvement of
symptoms in a subset of patients. Although the exact
mechanism of improvement with pacing remains unknown,
the decrease in gradient may be caused by timing of septal
contraction but may also reflect long-term remodeling.369
Although there was an initial enthusiasm for dual-chamber
pacing as a primary treatment for patients with obstructive
HCM, subsequentRCTsdemonstrated long-lasting beneficial
results in only a small minority of patients, whereas most
perceived improvement was judged to be a placebo ef-
fect.283,284,367 A trial of dual-chamber pacing may be consid-
ered for symptomatic patients with obstruction in whom an
ICD has already been implanted for high-risk status.
6.2.2.6.1. Results of DDD Pacing. Initial cohort studies of
the results ofdual-chamberpacing inpatientswithobstructive
HCM and limiting symptoms showed symptomatic improve-
ment in almost 90% of patients, accompanied by an improve-
ment in exercise time and a reduction in gradient.368-371
However, there have been 3 randomized crossover trials ingery c December 2011
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pacing but also underwent a back-up AAI mode (no pacing)
as a control arm.283,284,367 DDD pacing consists of continu-
ously sensing or pacing the atrium and pacing the right ven-
tricular apex. The overall reduction in outflow tract gradient
was modest (25% to 40%) with substantial variation among
individual patients. Objective measurements of exercise ca-
pacity were improved during DDD pacing versus baseline,
but there was no significant difference comparing the AAI
back-upmodewith continuousDDDpacing.Although symp-
tomatic improvementwas reported by themajority of patients
following continuousDDDpacing, a similar frequency of im-
provement was reported by patients during the AAI mode
(control mode without pacing). These findings suggest a pla-
cebo effect as well as a ‘‘training effect’’ contributing to the
initial symptomatic improvement of patients undergoing
dual-chamber pacing.283,284,372
Overall, the percentage of patients with sustained symp-
tomatic improvement from continuous dual-chamber pac-
ing varies from 30% to 80%.292,294,295,366 A consistent
improvement in symptoms with a decrease in gradient
and objective improvement in exercise duration is seen in
<50% of patients. The overall success rate in terms of
symptom relief and gradient reduction is significantly lower
than that seen in patients who undergo septal myectomy.
The mean residual gradient after septal myectomy is<10
mm Hg compared with a 40 to 50 mm Hg gradient after
dual-chamber pacing.283,284,295,369 There is no reliable pre-
dictor of success for dual-chamber pacing, including the re-
sults of acute hemodynamic studies or morphologic
echocardiographic features.295,367,373 Patients >65 years
of age may be a subgroup who achieve the greatest bene-
fit.283 There are no data that indicate dual-chamber pacing
either reduces the risk of SCD in patients with HCM or
alters the underlying progression of disease.283,369 Dual-
chamber pacing has not been shown to be beneficial for
patients with nonobstructive HCM.374
6.2.2.6.2. DDDPacing: Caveats. Athoroughunderstanding
of the complex interplay between pacemaker programming
and the hemodynamics of HCM is necessary to achieve
possible beneficial results from this therapy. It is necessary
to optimize the atrioventricular delay because too short an in-
terval results in hemodynamic deterioration and too long an
atrioventricular interval without complete preexcitation of
the ventricle results in an inadequate response.375 The
position of the pacemaker lead is important, requiring distal
apical capture for optimal hemodynamic results.376 Program-
ming of rate-adaptive pacing is also necessary so that full
preexcitation of the ventricle is obtained during exercise.
6.2.2.6.3. Pacing and ICDs. Patients with HCM are at in-
creased risk for ventricular tachyarrhythmias and SCD.
Comprehensive SCD risk stratification should beThe Journal of Thoracic and Carperformed in all patients with HCM (Section 6.3.1). How-
ever, current SCD risk stratification does not identify all
patients at risk for ventricular arrhythmias and SCD.377
An ICD has been shown to be effective at aborting SCD
in patients with HCM.55 Consideration of an ICD if a pac-
ing device is indicated for either rhythm or hemodynamic
indications is controversial in contrast to the situation in
patients with established risk factors for SCD.
6.2.3. Patients With LV Systolic Dysfunction—
Recommendations
Class I
1. Patients with nonobstructive HCM who develop systolic dysfunc-
tion with an EF less than or equal to 50% should be treated accord-
ing to evidence-basedmedical therapy for adults with other forms of
heart failure with reduced EF, including angiotensin-converting en-
zyme inhibitors, angiotensin receptor blockers, beta blockers, and
other indicated drugs.39,378 (Level of Evidence: B)
2. Other concomitant causes of systolic dysfunction (such as CAD)
should be considered as potential contributors to systolic dysfunc-
tion in patients with HCM. (Level of Evidence: C)
Class IIb
1. ICD therapy may be considered in adult patients with advanced (as
defined by NYHA functional class III or IV heart failure) nonob-
structive HCM, on maximal medical therapy, and EF less than or
equal to 50%, who do not otherwise have an indication for an
ICD.39 (Level of Evidence: C)
2. For patients with HCM who develop systolic dysfunction, it may
be reasonable to reassess the use of negative inotropic agents previ-
ously indicated, for example, verapamil, diltiazem, or disopyramide,
and to consider discontinuing those therapies. (Level of Evidence: C)
Although HCM has typically been excluded from RCTs
in heart failure, there is no compelling reason to believe
that the etiology of reduced EF heart failure differs suffi-
ciently to disqualify many highly effective, evidence-
based, guideline-directed therapies for heart failure with
reduced EF.379 Standard heart failure therapies should be
implemented in patients with HCM when the EF is
50% for patients with CAD.39
The discovery of reduced EF in the setting of HCM is not
inconsistentwith the knownnatural history ofHCMbut is un-
common (approximately 3%) and should prompt an appro-
priate search for other potential contributing causes of LV
dysfunction.39 Those causes should include, but are not lim-
ited to, CAD, valvular heart disease, andmetabolic disorders.
Patients with HCM were not included in the primary pre-
vention ICD trials for patients with heart failure due to CAD
or dilated cardiomyopathy (and reduced EF). Prophylatic
ICD implantation is nevertheless the generally accepted clin-
ical practice for HCM patients with systolic dysfunction. Fur-
thermore, despite theabsence of clinical trials orobservational
data, the use of negative inotropic drugs that would otherwise
be discouraged in the setting of conventional heart failure
with reduced EF can be considered in patients with HCM.diovascular Surgery c Volume 142, Number 6 e179
Clinical Guideline Gersh et al6.2.4. Selection of Patients for Heart Transplantation—
Recommendations
Class I
1. Patients with advanced heart failure (end stage*) and nonobstruc-
tive HCMnot otherwise amenable to other treatment interventions,
with EF less than or equal to 50% (or occasionally with preserved
EF), should be considered for heart transplantation.39,381 (Level of
Evidence: B)
2. Symptomatic children with HCM with restrictive physiology who
are not responsive to or appropriate candidates for other therapeu-
tic interventions should be considered for heart transplanta-
tion.382,383 (Level of Evidence: C)
Class III: Harm
1. Heart transplantation should not be performed in mildly symptom-
atic patients of any age with HCM. (Level of Evidence: C)
In general, the indications for heart transplantation in-
clude advanced heart disease, typically with NYHA func-
tional class III or IV symptoms that are refractory to all
other reasonable interventions. Transplant referral for re-
fractory symptoms does not absolutely require reduced
EF, although this treatment strategy is rarely recommended
and performed in the presence of preserved EF. For patients
with HCM, outcome after heart transplantation is not differ-
ent from that of patients with other heart diseases.39,384,3856.3. Prevention of SCD
6.3.1. SCD Risk Stratification—Recommendations
Class I
1. All patients with HCM should undergo comprehensive SCD risk
stratification at initial evaluation to determine the presence of the
following:50,53,55,127,128,386-392 (Level of Evidence: B)
a. A personal history for ventricular fibrillation, sustained VT, or
SCD events, including appropriate ICD therapy for ventricular
tachyarrhythmias.y
b. A family history for SCD events, including appropriate ICD
therapy for ventricular tachyarrhythmias.y
c. Unexplained syncope.
d. Documented NSVT defined as 3 ormore beats at greater than or
equal to 120 bpm on ambulatory (Holter) ECG.
e. Maximal LV wall thickness greater than or equal to 30 mm.
Class IIa
1. It is reasonable to assess blood pressure response during exercise as
part of SCD risk stratification in patients with HCM.89,127,390 (Level
of Evidence: B)*Characterized by systolic dysfunction (EF50%), often associated with LV remod-
eling, including cavity enlargement and wall thinning, and because of diffuse myo-
cardial scarring.
yAppropriate ICD discharge is defined as ICD therapy triggered by VTor ventricular
fibrillation, documented by stored intracardiac electrogram or cycle-length data, in
conjunction with the patient’s symptoms immediately before and after device dis-
charge.
e180 The Journal of Thoracic and Cardiovascular Sur2. SCD risk stratification is reasonable on a periodic basis (every 12 to
24months) for patients withHCMwho have not undergone ICD im-
plantation but would otherwise be eligible in the event that risk fac-
tors are identified (12 to 24 months). (Level of Evidence: C)
Class IIb
1. The usefulness of the following potential SCD risk modifiers is un-
clear but might be considered in selected patients with HCM for
whom risk remains borderline after documentation of conventional
risk factors:
a. CMR imaging with LGE.184,188 (Level of Evidence: C)
b. Double and compound mutations (ie,>1). (Level of Evidence: C)
c. Marked LVOT obstruction.45,127,143,390 (Level of Evidence: B)Class III: Harm
1. Invasive electrophysiologic testing as routine SCD risk stratifica-
tion for patients with HCM should not be performed. (Level of
Evidence: C)
See Online Data Supplement 4 for additional data re-
garding SCD risk stratification.
A minority of clinically recognized patients with HCM
are judged to be at increased risk for SCD, with a rate of
about 1% per year.53,55,386-389 ICDs offer the only effec-
tive means of preventing SCD and prolonging life in
patients with HCM.55 Selection of patients who are
appropriate for implantation for primary as opposed to
secondary prevention can be a difficult clinical decision,
owing to the individuality of each patient and family, vari-
able definitions for risk markers, sparse clinical data, the
relative infrequency of both HCM and SCD in most clin-
ical practices, and the cumulative morbidity of living with
an ICD.
6.3.1.1. Established Risk Markers
6.3.1.1.1. Prior Personal History of Ventricular Fibrilla-
tion, SCD, or Sustained VT. As expected, patients with
HCMwho have experienced SCD or sustained VT represent
the highest risk for subsequent arrhythmogenic events. The
annualized rate of subsequent events is approximately 10%
per year, although it has been shown that individuals may
have no recurrent events or may have decades-long arrhyth-
mia-free intervals between episodes.55,387-389,393
6.3.1.1.2. Family History of SCD. It has been recognized
that SCD events can cluster in families. Notably, some stud-
ies have not demonstrated an independent link between
family history of SCD and risk for individual patients on
multivariate analysis,50,390,394 whereas others have sug-
gested that family history is an independent predictor.394
These differences may be explained in part by the relative
infrequency of events but also likely reflect variability in
the definition of a family history of SCD. Some studiesgery c December 2011
Gersh et al Clinical Guidelinehave used a definition of SCD in2 first-degree relatives,50
whereas others have counted a single event.127,390 None of
these studies have rigorously accounted for the total number
of clinically apparent patients with HCM in each family, nor
have they included SCD in more remote relations (eg,
cousins, uncles, aunts, grandparents).
6.3.1.1.3. Syncope. Syncope represents a complex symp-
tom with a multifactorial etiology that requires a careful
clinical history before it can be considered a potential
marker for SCD.50,392 In one analysis, syncope that was un-
explained or thought to be consistent with arrhythmia (ie,
not neurally mediated) showed a significant independent as-
sociation with SCD only when the events occurred in the re-
cent past (<6 months) but not if the syncopal episodes
occurred>5 years before the clinical visit.392 One other
large study reports a similar independent association be-
tween recent unexplained syncope and SCD.127 Another
study showed that it was the interaction between syncope
and family history that was an important prognostic
marker.50
6.3.1.1.4. Nonsustained Ventricular Tachycardia. Although
sustained ventricular arrhythmia is clearly associated with
SCD, the data for NSVT are less robust. Only 1 of 5 studies
showed a univariate association between NSVT on 24-hour
ambulatory monitors and SCD,50,128,389,395-397 whereas 1
contemporary and larger study showed that NSVT is inde-
pendently associated with SCD on multivariate analysis127
and is more important in younger patients (<30 years of
age).129 Furthermore, exercise-induced NSVT has been
found to have independent association with SCD.398 NSVT
probably should not be considered in a simply binary manner
(ie, as either positive or negative), and there may be some
value in long-term ambulatory monitoring when NSVT is
discovered on the screening 24-hour assessment. Intuitively,
it would seem appropriate to place more weight on frequent,
longer, and/or faster episodes of NSVT; however, there have
been no systematic investigations of whether number of ep-
isodes and duration or ventricular rate of episodes of
NSVT definitely have an impact on SCD risk.
6.3.1.1.5. Maximum LV Wall Thickness. The relationship
between severity of LV hypertrophy and SCD has been in-
vestigated in several studies predicated on the concept that
the more severe the disease expression, the more likely the
individual patient is to experience adverse events. Most, but
not all,51,399 studies have shown at least a univariate associ-
ation between maximum wall thickness and SCD,389,396,399
whereas other large studies have shown that when magni-
tude of hypertrophy is30 mm, there is an independent as-
sociation with SCD.50,161,392 Notably, 3 reports derive from
overlapping samples of patients50,127,391 have shown differ-
ent strengths in the relationship between wall thickness andThe Journal of Thoracic and CarSCD that may reflect a slight variance in exclusion criteria,
definition of other risk markers, and the number of risk
markers included in multivariate analysis. It is crucial to
recognize that the risk estimate does not abruptly increase
for patients with 30 mm wall thickness but rather in-
creases in a linear fashion161 and appears to carry more
prognostic significance in younger patients.400 With this
in mind, a young adult with hypertrophy that approaches
30 mm may have similar or greater SCD risk than older pa-
tients with maximum wall thickness 30 mm.
6.3.1.1.6. Abnormal Blood Pressure Response During Exer-
cise. For up to a third of patients with HCM, there is an in-
appropriate systemic systolic blood pressure response
during exercise testing (defined as either a failure to in-
crease by at least 20 mm Hg or a drop of at least 20 mm
Hg during effort).89,90 It has been postulated that this find-
ing is a risk factor for SCD. Two studies have shown a uni-
variate association between this finding and subsequent
SCD.50,89,127,390 It is also unclear how this finding is related
to the well-recognized increase in dynamic LVOT obstruc-
tion that occurs with effort, a hemodynamic condition that is
readily modifiable with medication or mechanical proce-
dures. It would be appropriate to reassess this particular
SCD risk marker following invasive therapies to relieve out-
flow tract obstruction, although there are no data in such
patients.
6.3.1.2. Other Potential SCD Risk Modifiers
6.3.1.2.1. LVOT Obstruction. Although some studies have
not found a significant association between LVOT obstruc-
tion and SCD,45,47,161 other studies have found higher rates
of SCD among patients with resting gradients 30 mm
Hg127,390 and that the risk is positively correlated with se-
verity of LVOTobstruction.127 Conversely, relief of outflow
tract obstruction through surgical myectomy is associated
with very low rates of SCD.61,321 A limitation to using
LVOT obstruction as an independent risk marker is that
the obstruction in HCM is dynamic and highly variable
from hour to hour to the extent that no gradient may be de-
tectable during one evaluation, whereas the next day (or
even a short time later during the same day), a moderate
to severe gradient may be apparent.81,401 This variability
makes it not only difficult to assess risk in the individual pa-
tient, but it also likely explains the difficulty in demonstrat-
ing statistical significance in smaller studies. Whether
exercise-induced augmentation of the gradient is one of
the mechanisms that results in syncope and/or abnormal
blood pressure response during exercise has not been com-
pletely addressed.
6.3.1.2.2. LGE on CMR Imaging. There has been consider-
able interest in promoting LGE on CMR imaging asdiovascular Surgery c Volume 142, Number 6 e181
zSCD risk modifiers are discussed in Section 6.3.1.2.
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lieved to represent myocardial fibrosis or scarring, it has
been hypothesized that LGE may represent myocardium
prone to ventricular tachyarrhythmia.188 Indeed, LGE has
been associated with NSVT and ventricular ectopy but has
not been associated with clinical SCD events or ICD dis-
charge in published studies.184,185,188 More recent studies
have shown a relationship between LGE and SCD and heart
failure but with low positive predictive accuracy.186,187
LGE is a common feature observed in patients with
HCM, and there is no consensus on the appropriate imaging
protocols or threshold for detection of LGE. Both of these
features currently limit the role of LGE as an independent
risk marker.
6.3.1.2.3. LV Apical Aneurysm. A subset of patients with
HCM (prevalence about 2%) develop a thin-walled LV
apical aneurysm associated with regional scarring182 and
more adverse clinical events during follow-up, including
progressive heart failure and evolution into the end-stage
phase as well as SCD. Although data on LV aneurysms
in HCM are limited, this abnormality may warrant consid-
eration in SCD risk-assessment strategies.
6.3.1.2.4. Genetic Mutations. SCD may cluster in certain
families with HCM, and the possibility that specific sarco-
mere mutations may confer SCD risk has been hypothe-
sized. Indeed, several early studies of HCM pedigrees
implicated certain mutations as ‘‘malignant.’’107,114,402,403
However, subsequent studies of less selected consecutive
patients with HCM found that it was problematic to infer
likelihood of SCD events on the basis of the proposed mu-
tations, because in some instances the rate of adverse events
(and prevalence of associated SCD risk markers) was lower
in patients with ‘‘malignant’’ mutations than it was in those
with mutations believed to be ‘‘benign.’’95,404-406 The data
from unselected consecutive outpatients suggest that most
mutations are ‘‘novel’’ and limited to particular families
(‘‘private’’ mutations). Therefore, routine mutational
screening would appear to be of little prognostic value in
HCM.
6.3.1.3. Utility of SCD Risk Markers in Clinical Practice
Other than cardiac arrest, each of the HCM risk factors
has low positive predictive value (approximately 10% to
20%) and modestly high negative predictive value (85%
to 95%). Multiple risk markers in individual patients
would intuitively suggest greater risk for SCD; however,
the vast majority of patients with 1 risk marker will
not experience SCD, and simple arithmetic summing of
risk markers is not precise because of the uncertainty im-
plicit in assigning a relative weight to any individual risk
factor.50,51,407 Notably, in the international HCM-ICD reg-
istry,55 the number of risk factors did not correlate with thee182 The Journal of Thoracic and Cardiovascular Surrate of subsequent appropriate ICD discharges among pre-
sumably high-risk patients selected for ICD placement.
These data suggest that the presence of a single risk
marker may be sufficient to warrant ICD placement in
many patients, but these decisions need to be individual-
ized with regard to age, the strength of the risk factor,
and the risk-benefit of lifelong ICD therapy.55,408
6.3.2. Selection of Patients for ICDs—Recommendations
Class I
1. The decision to place an ICD in patients with HCM should include
application of individual clinical judgment, as well as a thorough
discussion of the strength of evidence, benefits, and risks to allow
the informed patient’s active participation in decision making
(Figure 4).53-56 (Level of Evidence: C)
2. ICD placement is recommended for patients with HCM with prior
documented cardiac arrest, ventricular fibrillation, or hemodynam-
ically significant VT.55,387-389 (Level of Evidence: B)
Class IIa
1. It is reasonable to recommend an ICD for patients with HCMwith:
a. Sudden death presumably caused by HCM in 1 or more first-
degree relatives.394 (Level of Evidence: C)
b. A maximum LV wall thickness greater than or equal to 30
mm.50,51,161,400 (Level of Evidence: C)
c. One or more recent, unexplained syncopal episodes.392 (Level of
Evidence: C)
2. An ICD can be useful in select patients with NSVT (particularly
those<30 years of age) in the presence of other SCD risk factors
or modifiers.z53,129 (Level of Evidence: C)
3. An ICD can be useful in select patients withHCMwith an abnormal
blood pressure response with exercise in the presence of other SCD
risk factors or modifiers.z89,90,390 (Level of Evidence: C)
4. It is reasonable to recommend an ICD for high-risk children with
HCM, based on unexplained syncope, massive LV hypertrophy, or
family history of SCD, after taking into account the relatively
high complication rate of long-term ICD implantation. (Level of
Evidence: C)
Class IIb
1. The usefulness of an ICD is uncertain in patients with HCM with
isolated bursts of NSVT when in the absence of any other SCD
risk factors or modifiers.z,53 (Level of Evidence: C)
2. The usefulness of an ICD is uncertain in patients with HCMwith an
abnormal blood pressure response with exercise when in the ab-
sence of any other SCD risk factors or modifiers,z particularly in
the presence of significant outflow obstruction.89,90,390 (Level of Ev-
idence: C)
Class III: Harm
1. ICD placement as a routine strategy in patients with HCM without
an indication of increased risk is potentially harmful. (Level of Ev-
idence: C)
2. ICD placement as a strategy to permit patients with HCM to partic-
ipate in competitive athletics is potentially harmful. (Level of Evi-
dence: C)gery c December 2011
FIGURE 4. Indications for ICDs in HCM. *SCD risk modifiers include established risk factors and emerging risk modifiers (Section 6.3.1.2). BP, Blood
pressure; ICD, implantable cardioverter-defibrillator; LV, left ventricular; SCD, sudden cardiac death; SD, sudden death; and VT, ventricular tachycardia.
Gersh et al Clinical Guideline3. ICD placement in patients who have an identified HCM genotype in
the absence of clinical manifestations of HCM is potentially harm-
ful. (Level of Evidence: C)
Although the overall rate of SCD in HCM is approxi-
mately 1% per year, clearly there are individuals at higher
risk for whom prophylactic therapy may be indicated. Phar-
macologic therapy has not been demonstrated to provide
protection from SCD. Conversely, the ICD has proved to
be effective in terminating life-threatening ventricular
tachyarrhythmias in HCM, altering the natural course of
the disease and prolonging life.
The decision for placement of primary prevention ICD in
HCM often involves a large measure of individual clinical
judgment, particularly when the evidence for risk is ambig-
uous. The potential for SCD needs to be discussed with each
fully informed HCM patient and family member in the con-
text of their concerns and anxieties and should be balanced
against the risks and benefits of proposed prophylactic ICD
strategy. Consideration of the patient’s age is warranted,
particularly because device complications are more likelyThe Journal of Thoracic and Carin children and young adults over the long period of
follow-up.55,408
6.3.2.1. Results of ICD Therapy in HCM
There have been 2 reports from an international, multi-
center registry of patients with HCM who have undergone
ICD placement on the basis of the clinical perception of
SCD sufficient to justify device therapy.54,55 Among pa-
tients who received a device as a result of a prior personal
history of cardiac arrest or sustained ventricular arrhythmia
(secondary prevention ICD), the annualized rate of subse-
quent appropriate ICD discharge was 10% per year. Pa-
tients with primary prevention ICDs placed on the basis
of 1 or more of the conventional risk markers experienced
appropriate ICD therapy at a rate of approximately 4%
per year.54,55 Among these patients, who were selected for
ICD placement based on clinical risk perceptions, the num-
ber of risk markers present did not predict subsequent de-
vice discharge. Whether this is related to the highly
selected population involved or possibly because andiovascular Surgery c Volume 142, Number 6 e183
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mous with SCD prevention is uncertain. The relative weight
of the individual risk markers in predicting device discharge
rate has not been reported.55,408
6.3.2.2. Complications of ICD Therapy in HCM
It is important to recognize and discuss with patients po-
tential ICD-related complications (both procedural and
long term) that occur at a rate of 4% per year in patients
with HCM.408 Potential early problems may include pneu-
mothorax, pericardial effusion, pocket hematoma, acute
pocket infection, and/or lead dislodgment. Late complica-
tions include upper extremity deep venous thrombosis,
lead dislodgment, infection, high defibrillation threshold
necessitating lead revision, and inappropriate shocks, that
is, shocks triggered by supraventricular arrhythmias, sinus
tachycardia, lead fractures or dislodgment, oversensing,
double counting, and programming malfunctions.
Reported rates of complications include approximately
25% of patients with HCM who experienced inappropriate
ICD discharge; 6% to 13% who experienced lead compli-
cations (fracture, dislodgment, oversensing); 4% to 5%
who developed device-related infection; and approximately
2% to 3%who experienced bleeding or thrombosis compli-
cations.55,408 The rate of inappropriate shocks and lead frac-
tures appears to be higher in children than in adults, largely
because their activity level and body growth places contin-
ual strain on the leads, which are the weakest link in the sys-
tem.386 This issue is of particular concern, given the long
periods that young patients will have prophylactically im-
planted devices.
Industry-related ICD problems have fnected patients
with HCM. Prominent recalls have included defective gen-
erators leading to several deaths409 and small-diameter
high-voltage leads prone to fracture.410,411 The implant
procedure has been largely free of significant risk, without
reported deaths, although selected patients with extreme hy-
pertrophy or who have received amiodarone may require
high-energy output generators or epicardial lead
systems.412
6.3.2.3. Overall Risk Assessment and Selection of Patients
for ICD Therapy
The decision to recommend and pursue ICD placement is
a complex process that can be oversimplified. The individ-
uality of each patient and family circumstance, including
level of anxiety, life situation, and views on death, and indi-
vidual assessment of the relativeweight of potential benefits
compared with potential risks must be processed for each
patient. The low positive predictive value of any of the
SCD risk factors and the variability in the strength of data
also introduce a degree of ambiguity to the SCD risk assess-
ment and dramatically limit the applicability of counting
the number of risk factors as the primary risk assessmente184 The Journal of Thoracic and Cardiovascular Surmethodology. Based on the weight of evidence, plausibility,
and consensus judgment reflecting clinical experience, it is
recognized that patients with massive hypertrophy, a family
history of HCM-related SCD, or recent unexplained syn-
cope would probably benefit from ICD placement. Apart
from these, it was believed that a combination of conven-
tional risk factors and other risk modifiers provided the op-
timal identification of the subset of patients with HCM with
sufficient risk of SCD to warrant strong consideration of
ICD placement (Figure 4).6.3.2.4. Selection of ICD Device Type—Recommendations
Class IIa
1. In patients with HCM who meet indications for ICD implantation,
single-chamber devices are reasonable in younger patients without
aneed foratrial or ventricularpacing.410,413-415 (Level ofEvidence:B)
2. In patients with HCM who meet indications for ICD implantation,
dual-chamber ICDs are reasonable for patients with sinus brady-
cardia and/or paroxysmal AF.413 (Level of Evidence: C)
3. In patients with HCM who meet indications for ICD implantation,
dual-chamber ICDs are reasonable for patients with elevated rest-
ing outflow gradients greater than 50 mm Hg and significant heart
failure symptoms who may benefit from right ventricular pacing
(most commonly, but not limited to, patients >65 years of
age).283,284,367,413 (Level of Evidence: B)
All ICDs incorporate a right ventricular lead that has both
pacing and defibrillation capabilities. ICDs are available as
single-chamber, dual-chamber, or 3-chamber (ie, cardiac re-
synchronization therapy) devices. Whether a patient receives
a dual-chamber or cardiac resynchronization therapy system
depends on other considerations, including the need for atrial
pacing, enhanced supraventricular tachycardia (SVT) dis-
crimination, right ventricular pacing, and importantly, consid-
eration of the patient’s age and the subsequent longevity of the
lead and ICD system.416 In patients with LVOT obstruction,
particularly the elderly, in whom ICDs are indicated, dual-
chamber pacing may have the potential to reduce gradient
and symptoms in some patients (Section 6.2.2.6).
ICD leads fail at a rate of 0.5% to 1% per year, although
there are data showing that failure rates are increased in
a younger, healthier population.410 When a lead fails, a new
lead is needed; the old lead can remain in, which over time
places the patient at risk for venous obstruction, or the old
leadmay be removed, which carries a significant risk of mor-
bidity and mortality. In young patients with HCM, an ICD
may be needed for up to 70 years. There is no expectation
that a single lead will remain functional for that amount of
time. Thus, in general, the younger the patient, the more ap-
propriate it is for single-chamber devices to be used to de-
crease the amount of hardware in the venous system.
Dual-chamber devices have been advocated to increase
the ability of the ICD to differentiate between SVTand ven-
tricular arrhythmias. Data to support this hypothesis are
mixed with some studies showing no difference betweengery c December 2011
TABLE 4. Recommendations for the acceptability of recreational
(noncompetitive) sports activities and exercise in patients with HCM*
Intensity level Eligibility scale for HCMy
High
Basketball (full court) 0
Basketball (half court) 0
Body buildingz 1
Gymnastics 2
Ice hockeyz 0
Racquetball/squash 0
Rock climbingz 1
Running (sprinting) 0
Skiing (downhill)z 2
Skiing (cross-country) 2
Soccer 0
Tennis (singles) 0
Touch (flag) football 1
Windsurfingx 1
Moderate
Baseball/softball 2
Biking 4
Hiking 3
Modest hiking 4
Motorcyclingz 3
Jogging 3
Sailingx 3
Surfingx 2
Swimming (laps)x 5
Tennis (doubles) 4
Treadmill/stationary bicycle 5
Weightlifting (free weights)zk 1
Low
Bowling 5
Brisk walking 5
Golf 5
Horseback ridingz 3
Scuba divingx 0
Skating{ 5
Snorkelingx 5
Weights (nonfree weights) 4
*Recreational sports are categorized according to high, moderate, and low levels
of exercise and graded on a relative scale (from 0 to 5) for eligibility, with 0 to 1
indicating generally not advised or strongly discouraged; 4 to 5, probably per-
mitted; and 2 to 3, intermediate and to be assessed clinically on an individual
basis. The designations of high, moderate, and low levels of exercise are equiv-
alent to an estimated >6, 4 to 6, and <4 metabolic equivalents, respectively.
yAssumes absence of laboratory DNA genotyping data; therefore, limited to clinical
diagnosis. zThese sports involve the potential for traumatic injury, which should be
taken into consideration for individuals with a risk for impaired consciousness.
xThe possibility of impaired consciousness occurring during water-related activities
should be taken into account with respect to the individual patient’s clinical profile.
kRecommendations generally differ from those for weight-training machines
(nonfree weights), based largely on the potential risks of traumatic injury associated
with episodes of impaired consciousness during bench-press maneuvers; otherwise,
the physiologic effects of all weight-training activities are regarded as similar
with respect to the present recommendations. {Individual sporting activity not as-
sociated with the team sport of ice hockey. Adapted with permission from Maron
et al.224
Gersh et al Clinical Guidelineinappropriate therapy for SVT417,418 and others showing
a benefit.419,420 Currently, discrimination of SVT is inade-
quate as a sole justification for a dual-chamber device in pa-
tients with HCM.
Whether cardiac resynchronization therapy devices are
useful for patients with HCM is unclear. There is a paucity
of published data on the use of cardiac resynchronization
therapy devices in patients with HCM and end-stage heart
failure.421
6.3.3. Participation in Competitive or Recreational Sports
and Physical Activity—Recommendations
Class IIa
1. It is reasonable for patients with HCM to participate in low-
intensity competitive sports (eg, golf and bowling).422,423 (Level of
Evidence: C)
2. It is reasonable for patients with HCM to participate in a range of
recreational sporting activities as outlined in Table 4.224 (Level of
Evidence: C)
Class III: Harm
1. Patients with HCM should not participate in intense competitive
sports regardless of age, sex, race, presence or absence of LVOTob-
struction, prior septal reduction therapy, or implantation of a cardi-
overter-defibrillator for high-risk status.58,59,422–426 (Level of
Evidence: C)
A number of large cohort studies from the United States
indicate that HCM is the most common cardiovascular cause
of SCD in young athletes, accounting for about one third of
these events.58,59,425,427 The American College of Cardiol-
ogy Bethesda Conference No. 36422,429 as well as the Euro-
pean Society of Cardiology guidelines423,429 indicate that
risk for SCD is increased during intense competitive sports
and also suggest that the removal of these individuals from
the athletic arena can diminish their risk. This principle is
the basis for disqualification of athletes with HCM from
sanctioned high school and college sports.422,429 It should
be underscored that these consensus recommendations for
competitive athletes are independent of those for noncompet-
itive, informal recreational sporting activities.224
General recommendations for recreational exercise in pa-
tients with HCM should be tailored to the individual’s de-
sires and abilities; however, certain guidelines prevail. For
example, aerobic exercise as opposed to isometric exercise
is preferable. Patients with HCM should avoid recreational
sports in which participation is intense and simulates com-
petitive organized athletics. Also, burst exertion, in which
an abrupt increase in heart rate is triggered (eg, sprinting
in half-court basketball), is less desirable than swimming
laps or cycling. Finally, it is prudent for such patients to
avoid physical activity in extreme environmental conditions
of heat, cold, or high humidity, with attention paid to main-
taining volume status. Detailed recommendations for indi-
vidual sports appear in Table 4.The Journal of Thoracic and Cardiovascular Surgery c Volume 142, Number 6 e185
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Class I
1. Anticoagulation with vitamin K antagonists (ie, warfarin, to an in-
ternational normalized ratio of 2.0 to 3.0) is indicated in patients
with paroxysmal, persistent, or chronic AF and HCM.60,430,431 (An-
ticoagulation with direct thrombin inhibitors [ie, dabigatranx] may
represent another option to reduce the risk of thromboembolic
events, but data for patients with HCM are not available.432) (Level
of Evidence: C)
2. Ventricular rate control in patients with HCMwith AF is indicated
for rapid ventricular rates and can require high doses of beta antag-
onists and nondihydropyridine calcium channel blockers.60,430
(Level of Evidence: C)
Class IIa
1. Disopyramide (with ventricular rate–controlling agents) and amio-
darone are reasonable antiarrhythmic agents for AF in patients
with HCM.430,433 (Level of Evidence: B)
2. Radiofrequency ablation for AF can be beneficial in patients with
HCMwho have refractory symptoms or who are unable to take an-
tiarrhythmic drugs.63-65,434,435 (Level of Evidence: B)
3. Maze procedure with closure of LA appendage is reasonable in pa-
tients with HCM with a history of AF, either during septal myec-
tomy or as an isolated procedure in selected patients. (Level of
Evidence: C)
Class IIb
1. Sotalol, dofetilide, and dronedarone might be considered alterna-
tive antiarrhythmic agents in patients with HCM, especially in
those with an ICD, but clinical experience is limited. (Level of
Evidence: C)
AF is an important cause of symptoms, morbidity, and
even mortality in patients with HCM.57,60 Diagnosis may
be made by an ECG during an AF episode or occasionally
on ambulatory Holter monitoring; use of an event recorder
may be helpful in some patients. Patients with HCM are at
increased risk of AF compared with age-matched cohorts,
but AF is seldom seen in young patients with HCM who
are<30 years of age and becomes more prevalent with
age. Risk factors for AF in HCM include age, congestive
heart failure, and LA function, diameter, and volume.60,436
A family history of AF is a risk factor in the Framingham
Heart Study, but there are no data in patients with HCM.
AF occurring in HCM may not be associated with symp-
toms or hemodynamic compromise in one third of patients
but is poorly tolerated in many others. There is evidence that
AF is an indicator of unfavorable prognosis, including in-
creased risk of HCM-related heart failure, death, and
stroke.60,437
Therapy for AF includes prevention of thromboembolic
stroke and controlling symptoms (Figure 5). The risk of sys-
temic embolization is high in patientswithHCMwithAFbutxDabigatran should not be used in patients with prosthetic valves, hemodynamically
significant valve disease, advanced liver failure, or severe renal failure (creatinine
clearance<15 mL/min).432
e186 The Journal of Thoracic and Cardiovascular Suris not related to the severity of symptoms.57,60 Occurrence of
paroxysmal, persistent, or chronic AF is a strong indication
for anticoagulation with a vitamin K antagonist.430 Whether
there is a threshold for AF that warrants anticoagulation is
unresolved; however, given the high risk of thromboembo-
lism in HCM, even patients with short episodes of AF should
be strongly considered for anticoagulation. Even a single ep-
isode of AF should be cause to consider anticoagulation
because the likelihood of recurrent AF is high. Aspirin
should be reserved for thosewho cannot or will not takewar-
farin or other oral anticoagulants, but its efficacy in HCM is
unestablished. The role of LA occlusion devices in HCM is
untested but could possibly be a future option in patients
who cannot tolerate anticoagulant therapy.438
Symptom control may be attained with adequate rate con-
trol, although many patients will require rhythm control.
Rate control is best maintained by beta blockers and calcium
channel blockers. High doses of these agents may be re-
quired. Digoxin may modestly reduce ventricular rate at
rest and to a lesser extent with exertion. Because there is
a paucity of data on rhythmcontrol in patientswithHCM, ev-
idence from other patient populations is extrapolated to
HCM. However, whether patients with HCM respond simi-
larly to antiarrhythmic agents is not clear. The ‘‘2011
ACCF/AHA/HRS Focused Updates Incorporated Into the
ACC/AHA/ESC2006Guidelines for theManagement of Pa-
tients With Atrial Fibrillation’’ state that disopyramide and
amiodarone are potential agents for rhythm control.430 The
limited published data on amiodarone suggest that it is safe
and effective for patients with HCM.439-442 Disopyramide
has been shown to be safe when prescribed for reduction of
LVOT obstruction, but its safety and efficacy in AF are not
well established.157,443 Dronedarone, an antiarrhythmic
agent similar to amiodarone but lacking the iodine moiety
and much of the long-term toxicity, has been approved for
use in the United States. There are no data regarding the ef-
ficacy of dronedarone or the use of flecainide and propafe-
none in patients with HCM. In the CAST (Cardiac
Arrhythmia Suppression Trial) trial, Class IC agentswere as-
sociatedwith an increasedmortality in patientswithCAD.444
Thus, caution is advisedwhen these agents are prescribed for
patients with HCM and their use should probably be limited
to individuals with an ICD. The management of atrial flutter
inHCM is similar to that in other disease states, including the
role of radiofrequency ablation.
The long-term benefits of radiofrequency ablation versus
antiarrhythmic drugs in patients with HCM remain to be es-
tablished. It does appear that early success and complica-
tion rates are similar between HCM and other forms of
heart disease or absence of heart disease.63-65,445 Thus, ra-
diofrequency ablation may play a role in the management
of AF, but further investigation is necessary. The surgical
maze procedure for AF has shown some limited success446;
however, whether a prophylactic or therapeutic surgicalgery c December 2011
FIGURE 5. Management of AF in HCM.AF, Atrial fibrillation;AV, atrioventricular; INR, international normalized ratio;PPM, permanent pacemaker;PVI,
pulmonary vein isolation.
Gersh et al Clinical Guidelinemaze procedure is indicated for patients undergoing other
open chest surgical procedures (ie, septal myectomy) is
unresolved.7. OTHER ISSUES
7.1. Pregnancy/Delivery—Recommendations
Class I
1. In women with HCM who are asymptomatic or whose symptoms
are controlled with beta-blocking drugs, the drugs should be contin-
ued during pregnancy, but increased surveillance for fetal brady-
cardia or other complications is warranted.41,140,447,448 (Level of
Evidence: C)
2. For patients (mother or father) with HCM, genetic counseling is in-
dicated before planned conception. (Level of Evidence: C)
3. In women with HCM and resting or provocable LVOT obstruction
greater than or equal to 50 mm Hg and/or cardiac symptoms not
controlled by medical therapy alone, pregnancy is associated with
increased risk, and these patients should be referred to a high-
risk obstetrician. (Level of Evidence: C)
4. Thediagnosis ofHCMamongasymptomaticwomen isnot considered
a contraindication for pregnancy, but patients should be carefully
evaluated in regard to the risk of pregnancy. (Level of Evidence: C)The Journal of Thoracic and CarClass IIa
1. For women with HCM whose symptoms are controlled (mild to
moderate), pregnancy is reasonable, but expert maternal/fetal med-
ical specialist care, including cardiovascular and prenatal monitor-
ing, is advised. (Level of Evidence: C)
Class III: Harm
1. For women with advanced heart failure symptoms and HCM, preg-
nancy is associated with excess morbidity/mortality. (Level of
Evidence: C)
Women with HCM safely experience pregnancy and la-
bor with minimal documented risks. The maternal mortality
rate is extraordinarily low and limited to those patients with
particularly advanced disease.449 Nevertheless, careful
evaluation of the mother and functional assessment is para-
mount during and just prior to pregnancy. Usually, special
medical precautions are unnecessary, and cesarean delivery
is not obligatory. However, women with advanced disease,
including progressive heart failure, severe diastolic dys-
function, VT, SVT, or marked LVOT obstruction, will re-
quire the care of a high-risk maternal/fetal medical teamdiovascular Surgery c Volume 142, Number 6 e187
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whose disease is well controlled with medical therapy
(beta blockers, verapamil, or disopyramide), there should
be no interruption of therapy, but careful maternal and fetal
monitoring is advised.157 For any woman of childbearing
age with HCM, it is paramount that genetic counseling be
advised before conception. Such patients should be coun-
seled prospectively about the risks of pregnancy and dis-
couraged if deemed necessary. Careful monitoring is
advisable in the first 24 hours after delivery, when large
fluid shifts can lead to acute pulmonary edema in the setting
of a noncompliant and hypertrophied left ventricle.7.2. Occupational Considerations
In 2002, the US Department of Transportation Federal
Motor Carrier Safety Administration published its ‘‘Cardio-
vascular Advisory Panel Guidelines for the Medical Exami-
nation of Commercial Motor Vehicle Drivers.’’ The
guidelines state that ‘‘irrespective of symptoms, a person
shouldnot be certified as a [commercialmotor vehicle] driver
if a firm diagnosis of [HCM] is made.’’.450(p83)k Although
consideration has subsequently been given to liberalizing
this restriction, the guidelines have not yet been revised.
The criteria for the disqualification of aircraft pilots with
cardiovascular disease are set by the Federal Aviation Ad-
ministration. Currently, HCM is regarded as generally in-
compatible with the highest grade aviation license for
commercial pilots, based on the unpredictable risk for im-
pairment in the cockpit attributable to HCM.4528. FUTURE RESEARCH NEEDS
Despite progress in the understanding of the etiology and
pathophysiology of HCM and in certain aspects of manage-
ment, more substantial insights into the fundamental and
clinical components of HCM provide considerable opportu-
nities to improve patient outcomes. The research priorities
in HCM were detailed in 2010 by a National Heart, Lung,
and Blood Institute working group.4538.1. Establishing the Cause of HCM
Over the past 20 years there have been major advances in
identification of genetic mutations that cause HCM. Con-
temporary data sets include>1400 mutations that primarily
occur in at least 8 genes that encode protein components ofkThe Federal Motor Carrier Safety Administration defines commercial motor vehicle
as a motor vehicle or combination of motor vehicles used in commerce to transport
passengers or property if the motor vehicle:
a. has a gross combination weight rating of 11 794 kg (26,001 lb) inclusive of
a towed unit(s) with a gross vehicle weight rating of 4536 kg (10,000 lb); or
b. has a gross vehicle weight rating of 11 794 kg (26,001 lb); or
c. is designed to transport 16 passengers, including the driver; or
d. is of any size and is used in the transportation of hazardous materials as defined
[by the Federal Motor Carrier Safety Administration].451
e188 The Journal of Thoracic and Cardiovascular Surthe sarcomere. Nonetheless, the genetic cause remains un-
known for a substantial proportion of patients with clinical
manifestations of HCM. Mutation-negative patients may
have LV hypertrophy attributable to another genetic (or
nongenetic) cause, with morphologic features that mimic
HCM but with distinctive pathophysiology and clinical out-
comes. Definition of the cause(s) of HCM morphology in
mutation-negative patients is important for the basic under-
standing of mechanisms that remodel the heart and for de-
termining whether or not the clinical practice guidelines
established for HCM are relevant in these patients. The abil-
ity to pool data from multiple registries is encouraged.
8.2. Defining the Link Between Genotype and
Phenotype
The emergence of newer sequencing methodologies pro-
vides unparalleled opportunities for defining the precise
mutation in most patients with HCM. Such information
can expand our understanding of the relationship between
genotype and phenotype in HCM, a link that remains in-
completely understood. Directing future efforts to identify
genetic modifiers (ie, genes that influence clinical expres-
sion) and environmental influences may expand under-
standing of the signaling pathways that are responsible for
phenotypic expression of HCM and related disease states.
These strategies also hold the potential to define novel ther-
apeutic targets that may attenuate the consequences of sar-
comere gene mutations, so that disease expression may be
delayed or conceivably prevented.
8.3. Management and Evaluation of HCMGenotype-
Positive/Phenotype-Negative Relatives
Gene-based diagnosis of HCM families has increased the
identification of genotype-positive/phenotype-negative in-
dividuals. There are many unanswered questions about
the natural history of these patients, including the identity
of factors that influence duration of the preclinical phase,
the likelihood of clinical identification by screening with
echocardiography (or CMR), the risk of SCD, and decisions
about the periodicity of clinical screening, the use of ICDs
for primary prevention, and participation in competitive
sports. Longitudinal data are needed to develop appropriate
management recommendations for this growing subset of
patients. In addition, as more information is accrued regard-
ing the signaling pathways that account for clinical mani-
festation associated with sarcomere protein gene
mutations, the study of therapeutic interventions aimed at
preventing the emergence of disease in preclinical patients
can be expected.
8.4. Clinical Significance of Myocardial Fibrosis
Myocardial fibrosis of the heart is increased in HCM be-
cause of an expansion of the interstitial matrix and also
myocardial replacement scarring (caused by microvasculargery c December 2011
Gersh et al Clinical Guidelineischemia and other factors). Consistent with histopatho-
logic findings, serum biomarkers of collagen turnover are
elevated in patients with clinically overt HCM. Recent stud-
ies in HCM models indicate that extracellular matrix re-
modeling predates the emergence of hypertrophy and may
contribute to diastolic dysfunction.18 Studies are needed
to ascertain whether prevention of interstitial (matrix) ex-
pansion or replacement scarring can improve HCM patho-
physiology and reduce late outcomes such as progressive
heart failure.
Replacement fibrosis and scarring can be visualized
(in vivo) by CMR gadolinium contrast enhancement.
Clearer understanding of the relationship between LGE, fi-
brosis, and clinical outcomes (including ventricular tachy-
arrhythmias and SCD) is needed.
8.5. Therapies to Directly Modify the HCM
Pathophysiology
The most widely used medical therapies for patients with
HCM (beta-adrenergic blockers, calcium channel blockers,
disopyramide) nonspecifically address aspects of the hemo-
dynamic abnormalities in patients with HCM, such as re-
ducing contractility to diminish the magnitude of outflow
tract obstruction. As noted above, a more sophisticated un-
derstanding of the links between the molecular pathophys-
iology and outcome is necessary in HCM to promote the
development of more relevant and targeted treatment strat-
egies.453 For example, characterization of the fundamental
biophysical defects produced by different mutations in sar-
comere proteins, assessment of energy requirements of the
heart in HCM, and assessment of the role of myocardial is-
chemia may lead to interventions that alter the natural his-
tory of disease expression.
8.6. Refining Risk Stratification for SCD
As noted in this document, identifiable clinical markers
are being used successfully in risk stratification for SCD
in HCM, assisting in recommendations about prophylactic
ICDs. Nonetheless, much ambiguity is often encountered
in using the current SCD risk stratification algorithm in in-
dividual patients, and there is a need to identify additional
and more sensitive/specific risk factors. Moreover, SCD
may occasionally occur in ‘‘low-risk’’ patients without con-
ventional risk factors. The assembly of larger cohorts from
multiple centers with detailed clinical, genetic, and lifestyle
information may improve SCD risk stratification and enable
more efficient use of ICDs.
8.7. Comparative Assessment of Septal Reduction
Strategies
The opportunity for percutaneous strategies to reduce out-
flow tract obstruction in HCM was realized through the de-
velopment of alcohol septal ablation. The potential of this
approach to provide clinical benefit in reducing symptomsThe Journal of Thoracic and Carwith lower patient morbidity and reduced healthcare expen-
ditures has been somewhat undermined by a concern for in-
creased ventricular arrhythmias following the procedure.
Robust information about the types and frequency of ad-
verse outcomes following alcohol septal ablation are needed
in addition to rigorous assessment of whether these events
are intrinsic to the procedure or related to underlying hyper-
trophic substrate, concomitant coronary or other comorbid
disease, or the advanced age at which patients receive this
therapy versus myectomy. In addition, observational regis-
tries might be useful to compare rates of HCM-related
death. Such comparisons of short- and long-term outcomes
of patients treated with alcohol septal ablation or myectomy
surgery would foster appropriate use of these strategies and
improve patient symptoms and outcomes.
8.8. Therapies to Treat and Prevent AF and Its
Associated Risks
AF is a common cause of morbidity and mortality in pa-
tients with HCM. Anticoagulation is well established in
other causes of AF and almost certainly extends to the
HCM patient with paroxysmal, chronic, or persistent AF.
However, whether anticoagulation should extend to those
patients with HCM who are at high risk of development
of AF is unclear. In addition, the relative roles of antiar-
rhythmic agents, radiofrequency ablation, and surgical
maze procedure need improved definition.
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APPENDIX 3. Abbreviation list
AF Atrial fibrillation
CAD Coronary artery disease
CMR Cardiovascular magnetic resonance
CTA Computed tomographic angiography
ECG Electrocardiogram
EF Ejection fraction
HCM Hypertrophic cardiomyopathy
ICD Implantable cardioverter-defibrillator
LA Left atrial
LGE Late gadolinium enhancement
LV Left ventricular
LVOT Left ventricular outflow tract
NSVT Nonsustained ventricular tachycardia
NYHA New York Heart Association
PET Positron emission tomography
RCT Randomized controlled trial
SAM Systolic anterior motion
SCD Sudden cardiac death
SPECT MPI Single photon emission computed tomography
myocardial perfusion imaging
SVT Supraventricular tachycardia
TEE Transesophageal echocardiogram
TTE Transthoracic echocardiogram
VT Ventricular tachycardia
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